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Abstract: 
Orofacial clefts (OFCs) are congenital dysmorphologies of the human face 
and oral cavity, with a global incidence of 1 per 700 live births. These 
anomalies exhibit multifactorial pattern of inheritance, with both genetic 
and environmental factors playing crucial roles. Many loci have been 
implicated in the aetiology of nonsyndromic cleft lip with or without cleft 
palate (NSCL/P) in populations of Asian and European ancestries through 
genome-wide association studies (GWAS) and candidate gene studies. 
However, few populations of African descent have been studied to date. 
Here, we show evidence of association of some loci with NSCL/P and 
nonsyndromic cleft palate only (NSCPO) in cohorts from Africa (Ghana, 
Ethiopia and Nigeria). We genotyped 48 SNPs that were selected from 
previous GWAS and candidate gene studies. These markers were 
successfully genotyped on 701 NSCL/P and 163 NSCPO cases, 1070 
unaffected relatives and 1078 unrelated controls. We also directly 
sequenced 7 genes in 184 nonsyndromic OFC (NSOFC) cases and 96 
controls from Ghana. Population-specific associations were observed in the 
case-control analyses of the sub-populations, with West African 
subpopulations (Ghana and Nigeria) showing similar pattern of 
associations. In meta-analyses of the case-control cohort, PAX7 (rs742071, 
p=5.10×10-03), 8q24 (rs987525, p=1.22×10-03) and VAX1 (rs7078160, 
p=0.04) were nominally associated with NSCL/P; MSX1 (rs115200552, 
p=0.01), TULP4 (rs651333, p=0.04), CRISPLD2 (rs4783099, p=0.02) and 
NOG1 (rs17760296, p=0.04) were nominally associated with NSCPO. 
Moreover, 7 loci exhibited evidence of threshold over-transmission in 
NSOFC cases in both transmission disequilibrium test (TDT) and family-
based association for disease traits (DFAM) analyses. Through DNA 
sequencing, we also identified two novel, rare, potentially pathogenic 
variants (p.Asn323Asp and p.Lys426IlefsTer6) in ARHGAP29. In conclusion, 
we have shown evidence of association of many loci with NSCL/P and 
NSCPO. To the best of our knowledge, our study is the first to demonstrate 
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Abstract 
Orofacial clefts (OFCs) are congenital dysmorphologies of the human face and oral cavity, with 
a global incidence of 1 per 700 live births. These anomalies exhibit multifactorial pattern of 
inheritance, with both genetic and environmental factors playing crucial roles. Many loci have 
been implicated in the aetiology of nonsyndromic cleft lip with or without cleft palate (NSCL/P) in 
populations of Asian and European ancestries through genome-wide association studies 
(GWAS) and candidate gene studies. However, few populations of African descent have been 
studied to date. Here, we show evidence of association of some loci with NSCL/P and 
nonsyndromic cleft palate only (NSCPO) in cohorts from Africa (Ghana, Ethiopia and Nigeria). 
We genotyped 48 SNPs that were selected from previous GWAS and candidate gene studies. 
These markers were successfully genotyped on 701 NSCL/P and 163 NSCPO cases, 1070 
unaffected relatives and 1078 unrelated controls. We also directly sequenced 7 genes in 184 
nonsyndromic OFC (NSOFC) cases and 96 controls from Ghana. Population-specific 
associations were observed in the case-control analyses of the sub-populations, with West 
African subpopulations (Ghana and Nigeria) showing similar pattern of associations. In meta-
analyses of the case-control cohort, PAX7 (rs742071, p=5.10×10-03), 8q24 (rs987525, 
p=1.22×10-03) and VAX1 (rs7078160, p=0.04) were nominally associated with NSCL/P; MSX1 
(rs115200552, p=0.01), TULP4 (rs651333, p=0.04), CRISPLD2 (rs4783099, p=0.02) and NOG1 
(rs17760296, p=0.04) were nominally associated with NSCPO. Moreover, 7 loci exhibited 
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evidence of threshold over-transmission in NSOFC cases in both transmission disequilibrium 
test (TDT) and family-based association for disease traits (DFAM) analyses. Through DNA 
sequencing, we also identified two novel, rare, potentially pathogenic variants (p.Asn323Asp 
and p.Lys426IlefsTer6) in ARHGAP29. In conclusion, we have shown evidence of association of 
many loci with NSCL/P and NSCPO. To the best of our knowledge, our study is the first to 
demonstrate any of these association signals in any African population. 
 
Keywords 
Africans, orofacial clefts, genetic heterogeneity, rare variants, Genome-Wide Association 
Studies (GWAS), candidate genes 
 
Introduction 
Human orofacial clefts (OFCs) are congenital malformations of the face and oral cavity, 
due to dysregulation of embryological processes. The global incidence of OFCs is 1 per 700 live 
births. However, race, ethnicity, geographical locations, environmental factors and socio-
economic status influence the incidence of OFCs (Gorlin et al. 2001). The highest incidence 
occurs in Asians, followed by populations of European ancestry, whereas African populations 
have the lowest incidence (Mossey and Modell, 2012). Though there is no national prevalence 
data for Ghana and Ethiopia, a prevalence estimate of 0.5 per 1000 has been observed for 
Nigeria (Butali et al. 2014a). These observations presuppose that the relative contributions of 
individual susceptibility genes may vary across different human populations. OFCs may be 
syndromic or nonsyndromic, with the syndromic forms presenting with other congenital 
anomalies. The aetiology of the more common nonsyndromic OFCs (NSOFCs) is complex, 
exhibiting multifactorial pattern of inheritance. NSOFCs are classified into nonsyndromic cleft lip 
with or without cleft palate (NSCL/P) and nonsyndromic cleft palate only (NSCPO), and these 
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two groups have heterogeneous genetic architecture. NSCL/P comprises nonsyndromic cleft lip 
only (NSCL) and nonsyndromic cleft lip and palate (NSCLP) (Dixon et al. 2011).  
 To date, six genome-wide association studies (GWAS) and a meta-analysis have been 
published for NSOFCs, with these signals demonstrating association with NSCL/P but not 
NSCPO. In a GWAS involving Europeans, association was observed between a locus in 
Chr8q.24 and NSCL/P (Birnbaum et al. 2009). The 8q.24 signal was subsequently replicated in 
another GWAS of NSCL/P in Europeans from US (Grant et al. 2009). A third GWAS that 
involved cohorts of European ancestries also revealed that two additional loci, 17q22 (NOG-1) 
and 10q25 (VAX1), were associated with NSCL/P. Other loci yielded suggestive association 
with NSCL/P:  15q13.3 (GREM1), 13q31.1 (SPRY2) and 2p21 (THADA) (Mangold et al. 2010). 
Employing trios of Asian and European ancestries, a GWAS implicated 20q12 (MAFB) and 
1p22.1 (ABCA4) in the aetiology of NSCL/P, with 17p13 (NTN-1) showing a suggestive 
association. Stratified analyses based on ancestries by the same GWAS showed that some 
signals were ancestry-specific: trios of European ancestry gave the strongest association for 
8q.24 whereas those of Asian ancestry were strongly associated with MAFB, ABCA4 and IRF6 
(Beaty et al. 2010). A meta-analysis also revealed additional NSCL/P susceptibility loci: THADA, 
SPRY2, 15q22.2 (TPM1) and 1p36 (PAX7) (Ludwig et al. 2012). Recently, a GWAS involving 
Asians implicated 16p13.3 (ADCY9) (Sun et al. 2015) in the aetiology of NSCL/P, whereas 
another GWAS involving dogs and Guatemala population gave a suggestive association for 
ADAMTS20 (Wolf et al. 2015). 
 In both pre- and post-GWAS era, candidate gene and replication studies have been 
instrumental in identifying cleft susceptibility loci. Pathogenic variants in IRF6 were shown to 
cause Van der Woude Syndrome (VWS) and Popliteal Pterygium Syndrome [PPS] (Kondo et al. 
2002). Subsequently, a missense variant in IRF6 (rs2235371) demonstrated over-transmission 
in NSCL/P cases of European ancestry (Zucchero et al. 2004). Another IRF6 locus, rs642961, 
has also been shown to be associated with NSCL/P but not NSCPO (Rahimov et al. 2008). 
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Corollary to these observations, some studies (Kerameddin et al. 2015; Birnbaum et al. 2009) 
have confirmed a role of IRF6 as NSCL/P risk loci in populations of Asian and European 
ancestries. Other candidate genes implicated in the aetiology of NSCL/P included MSX1 
(Rafighdoost et al. 2013), BMP4 (Suzuki et al. 2009), FOXE1 (Moreno et al. 2009), AXIN2 
(Letra et al. 2012), CRISPLD2 (Chiquet et al. 2007), NOG1 and FGFR2 (Leslie et al. 2015). 
 Among Africans, genetic studies on OFCs are limited. A study involving a Nigerian 
cohort implicated MSX1, but not other loci, in the aetiology of NSCL/P (Butali et al. 2011). Other 
studies that recruited Kenyans (Wheatherley-White et al. 2011) and Congolese (Figueiredo et 
al. 2014) could not replicate the association for cleft susceptibility loci among Africans, probably 
due to small sample size and population heterogeneity. Moreover, sequencing of GWAS loci in 
cohorts from Ethiopia and Nigeria reported some rare, potentially causative variants (Butali et al. 
2014b). Conducting genetic and genomics studies using cleft cohort from Africa may identify 
novel and population-specific signals. However, it is also important for us to investigate the role 
of identified signals and biologically relevant genes from existing European and Asian studies in 
the African population. The present study was aimed at replicating the association between 
reported GWAS and candidate gene loci in our NSCL/P cohort. We also tested the hypothesis 
that NSCL/P loci may also contribute to NSCPO susceptibility in Africans. Finally we screened 
for rare, potentially pathogenic variants in 7 candidate genes at risk loci that are usually 
associated with NSCL/P.  
 
Subjects and Methods 
We recruited 3,585 participants from Ghana, Ethiopia and Nigeria (Table 1; 
Supplemental Methods). All sample and data collection at various study sites were approved by 
the local Institutional Review Boards: KATH (Ghana) – CHRPE/AP/217/13, CMUL (Nigeria) – 
ADM/DCST/HREC/APP/1374 and Addis Ababa University Teaching Hospital (Ethiopia) - 
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3.10/027/2015. Before sample and data collection, written, informed consent was obtained from 
each participating family. DNA processing is shown in Supplemental Methods. 
 
SNP Selection 
We selected SNPs with MAF of 5% and above in the African population for genotyping; these 
have either been previously reported in peer review journals or were identified in animal studies 
and during our re-sequencing studies. These include SNPs that are associated with NSCL/P in 




 We genotyped 48 SNPs (Supplemental Table S1) on a total of 3,585 samples - 872 
NSOFC cases (163 NSCPO, 340 NSCL, 361 NSCLP, and 8 “un-typed”), 1635 unaffected 
relatives and 1078 unrelated controls, using 192.24 Fluidigm SNP Genotyping Protocol 
(Supplemental Methods). The “un-typed” (samples from probands) and other samples, however, 
failed quality control checks and were not included in the final statistical analyses (Table 1).  
 
Statistical Analyses for association studies 
 During quality control checks, we resolved Mendelian errors in case-parent triads and 
dropped from the final analyses samples that were not successfully genotyped on at least 95% 
of the 48 genotyped SNPs. We computed Hardy Weinberg Equilibrium (HWE) using PLINK 
(http://pngu.mgh.harvard.edu/~purcell/plink/). We then conducted case-control analyses to 
determine association in each subpopulation and meta-analyses of the three subpopulations 
based on Table 1. For this test, we used p<0.05 to denote nominal association and a Bonferroni 
Correction of 141 tests to ascertain a threshold for formal significance of p=3.54×10-4. The 141 
tests comprised of 47 SNPs that passed HWE × 3 cleft sub-phenotypes × 1 racial group x 1 
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test. Out of the 48 SNPs, only one failed HWE (p<0.05). Additional analyses to determine over-
transmission of the rare alleles were conducted using the Transmission Disequilibrium Test 
(TDT) and Family-Based Association for Disease Traits (DFAM). TDT used only the case-parent 
triad information (Table 1) while DFAM allowed us to combine both triad and dyad data. For 
these tests, the significant p-value was 0.05. Parent of Origin (POO) effects, and gene-gene 
interactions (epistasis) was also calculated. The probands in the case-control arm of the study 
(Table 1) are the same probands in the family-based studies. 
 
DNA Sequencing 
 We directly sequenced VAX1, PAX7, ARHGAP29, MSX1, FOXE1, BMP4 and MAFB in 
184 NSOFC cases (131 NSCL/P and 53 NSCPO) from Ghana using Sanger Sequencing 
(Supplemental Methods; Butali et al. 2014b). We also performed segregation analyses on 
observed potentially pathogenic missense, frameshift and splice site variants by sequencing 
available parental samples. We further sequenced 96 unrelated Ghanaian controls to ascertain 




In meta-analyses of the case-control cohorts from the three subpopulations, we 
successfully demonstrated nominal association between PAX7 (rs742071, p=5.10×10-03), 8q24 
(rs987525, p=1.22×10-03) as well as VAX1 (rs7078160, p=0.04) and NSCL/P; MSX1 
(rs115200552, p=0.01), TULP4 (rs651333, p=0.04), CRISPLD2 (rs4783099, p=0.02) and NOG1 
(rs17760296, p=0.04) were nominally associated with NSCPO (Table 2), with the direction of 
effect being the same as reported by earlier studies. Among Ethiopians (Supplemental Table 
S2), PAX7 (rs742071, p=5.57×10-03), IRF6 (rs642961, p=0.02), DYSF (rs2303596, p=2.31×10-
03), 8q24 (rs987525, p=7.82×10-04) and MAFB (rs13041247 and rs11696257, all with p=0.04) 
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were nominally associated with NSCL/P; ABCA4 (rs481931 and rs4147811, all with p=0.03) and 
NTN1 (rs8081823, p=0.03) were nominally associated with NSCPO. Moreover, subphenotype 
analyses of the Ethiopian NSCL/P cohort showed that the PAX7, DYSF, MSX1, SPRY2 
(rs9574565, p=7.05×10-03) and MAFB signals were particularly stronger for NSCL whereas the 
IRF6 (rs642961, p=9.11×10-03) and 8q24 (rs987525, p=1.07×10-03) signals were stronger for 
NSCLP (Supplemental Table S2). Among Ghanaians (Supplemental Table S3), ABCA4 
(rs560426, p=0.03) and VAX1 (rs7078160, p=0.03) were nominally associated with NSCLP, 
with subphenotype analyses of the NSCL/P cohort showing that the ABCA4 locus was strongly 
associated with NSCLP. ABCA4 (rs4147811, p=7.48×10-03) and CRISPLD2 (rs4783099, 
p=0.04) were nominally associated with NSCL/P and NSCPO, respectively, among Nigerians 
(Supplemental Table S4). Subphenotype analyses of the Nigerian NSCL/P (Supplemental Table 
S4) showed that PAX7 (rs742071, p=0.02) and ARHGAP29 (rs138751793, p=0.04) signals 
were stronger for NSCL whereas another SNP at the ABCA4 locus (rs481931, p=2.87×10-03) 
was strongly associated with NSCLP. However, none of these case-control associations passed 
Bonferroni correction. 
For TDT and DFAM (Tables 3 and 4) for all the three subpopulations, seven loci 
demonstrated formal significance with NSOFCs at p≤0.05. Formal significance for TDT and 
DFAM was evaluated at p≤0.05 because these are secondary analyses compared with case-
control analyses, and are not true independent tests. All family-based studies suggested that 
the minor allele of ABCA4 (rs560426) was over-transmitted in NSCLP cases among Africans. 
PAX7 (rs742071) also consistently showed evidence of over-transmission in NSCL cases in 
both TDT and DFAM. MSX1 (rs115200552) and AXIN2 (rs3923086) also demonstrated strong 
over-transmission in NSCLP cases in DFAM analyses whereas MTHFR (rs1801131) and DYSF 
exhibited over-transmission in NSCL cases in TDT and DFAM analyses, respectively. Only a 
SNP of VAX1 demonstrated over-transmission in NSCPO cases.  
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Parent of Origin Effects 
Parent-of-origin (POO) effects were not observed for almost all SNPs, except rs16260 of 
CDH1. For rs16260, a trend towards association (p=0.0764) was observed for all clefts. The 
rs16260 SNP exhibited a maternal imprinting or maternal over-transmission effect.  
 
Gene-Gene Interactions 
In Gene-Gene (G×G) or epistatic interactions, three SNPs exhibited evidence of 
epistasis with other SNPs. Each of these epistatic interactions yielded p=0.02. A SNP for 
ABCA4, rs560426, interacted with Chr6 rs2674394 (gene desert). Moreover, rs2303596 of 
DYSF interacted with rs3923086 of AXIN2. Finally, rs8069536 of NTN1 interacted with 
rs17820943, rs13041247 and rs11696257, all of MAFB. However, none of these G×G 
interactions passed Bonferroni correction.  
 
Direct DNA sequencing of seven selected genes 
We observed several rare and/or novel variants in the 7 genes that we sequenced 
(Table 5, Supplemental Table S5). Rare variants, as used here, refer to either a novel variant or 
a variant whose MAF is less than or equals to 1%. Some of these variants were predicted to be 
potentially pathogenic by various bioinformatics tools whereas others were depicted as benign. 
A de novo occurrence could not be demonstrated for any of these variants because either the 
variant was present in at least one parent or not both parents were available for segregation 
analysis. Lastly, some of the novel variants we observed occurred in controls (e.g. all VAX1 
variants) whereas others were not observed in controls (e.g. all ARHGAP29 variants). 
 
Discussion 
 We have successfully demonstrated associations (both nominal in case-control analyses 
and threshold in TDT and DFAM analyses) between some loci and NSCL/P in cohorts from 
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Africa. We also tested the hypothesis that these loci also contribute to NSCPO in Africans and 
observed some interesting associations. The 8q24 locus exhibited the strongest nominal 
significance with NSCL/P in case-control meta-analyses, with the trends suggesting this locus 
may be relevant in all three subpopulations. The test of heterogeneity also suggested largely the 
absence of heterogeneity at this locus among the three African populations. We observed that 
among Africans, the associated minor C allele of rs987525 (http://browser.1000genomes.org) 
conferred reduced susceptibility while the major A allele is the risk allele. Irrespective of these 
differences in minor alleles, our result is in harmony with earlier studies (Birnbaum et al. 2009; 
Grant et al. 2009; Mangold et al. 2010; Beaty et al. 2010; Ludwig et al. 2012) that demonstrated 
that the A allele of rs987525 is a risk allele for NSCL/P in Europeans. These observations 
suggest that the actual risk variant(s) is/are in linkage disequilibrium (LD) with the A allele of 
rs987525. Fine mapping of the African Haplotype (which is smaller in the 8q24 region) will help 
identify the risk variant(s). Our observations corroborate those made elsewhere (Beaty et al., 
2010; Murray et al., 2012) that suggested that the varied ethnic association of the rs987525 
allele largely depends on its MAF in various populations. Current evidence suggests that though 
the 8q24 window is a gene desert, it harbors very remote cis-acting craniofacial enhancer 
elements that regulate the expression of oncogenic MYC in the developing face; perturbation of 
this regulatory network leads to craniofacial dysmorphologies, including sporadic CL/P, in mice 
(Uslu et al. 2014).   
The C677T (rs1801133) SNP of MTHFR, but not A1298C (rs1801131), has largely been 
associated with reduced risk for NSCL/P in Asians (Martinelli et al. 2015; Pan et al. 2015; Zhao 
et al. 2014) and to some extent, in European-derived populations (Estandia-Ortega et al. 2014; 
de Aguiar et al. 2015), though not all studies (Sozen et al. 2009) replicated the association. 
Interestingly, we have demonstrated in TDT analyses that MTHFR is significantly associated 
with NSCL among Africans and that it is the C minor allele of A1298C (rs1801131) SNP that 
confers a reduced risk, suggesting A is the risk allele. AXIN2 has been implicated in the 
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aetiology of NSOFCs in multiple populations, except Africans, with rs3923086 demonstrating 
association with NSCLP among Asians (Letra et al. 2012).  Other studies (Mostowska et al. 
2012; Araujo et al. 2015) have replicated the association between AXIN2 and NSCL/P. Here, 
we have demonstrated that rs3923086 (AXIN2) is also associated with NSCLP among Africans 
in DFAM analyses. Other candidate genes (e.g. DYSF) also showed evidence of association 
with NSOFCs among Africans, buttressing the relevance of this approach in aetiologic “gene 
hunting”.  
 Other SNPs, other than already reported ones, may be responsible for the reported 
associations between certain loci and NSOFCs in some ethnicities. Through direct DNA 
sequencing of MSX1 gene, we observed over-transmission of the minor allele of rs115200552 
in NSOFC cases. Subsequent genotyping of this SNP in 3,585 individuals showed that this SNP 
was associated with NSCPO (p=0.01) in case-control meta-analyses, though family-based 
studies also suggest this marker may also be a risk allele for NSCLP. Earlier studies involving 
Africans from Nigeria implicated MSX1 in the aetiology of NSCL/P (Butali et al. 2011).  
We could not detect formal association between some GWAS and candidate gene loci 
and NSCL/P, presupposing either these loci may not play a role in the aetiology of NSCL/P in 
Africans or the genotyped SNPs may not be the tag SNPs for Africans. Lack of statistical power 
due to sample size and low MAF of the genotyped SNPs in Africans could also be possible 
reasons. For example, a SNP, rs2235371 of IRF6 which is in high LD and same locus as 
rs642961, that has been associated with NSCL/P mostly among Asians (Sun et al. 2015) and in 
some Europeans (Zucchero et al. 2004), does not exist in the African population 
(http://browser.1000genomes.org/index.html). It is also possible that even when no associations 
are detected between reported loci and NSOFCs, potentially pathogenic variants may be 
observed in NSOFC cases. Therefore, GWAS and whole genome sequencing (WGS) of 
NSOFC cases from Africa is required to detect more risk loci.   
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Subphenotype and sub-population analyses (even among the same racial group) may 
be crucial in detecting association between certain loci and NSOFCs. In both TDT and DFAM 
analyses, we observed that rs560426 of ABCA4 was associated with NSCLP but not the other 
OFC subphenotypes. Case-control analyses further suggested that the ABCA4 locus may be 
crucial in NSOFC aetiology in all three African populations. PAX7 (rs742071) exhibited nominal 
association with NSCL/P in case-control meta-analyses, with subpopulation analyses 
suggesting this signal originated mainly from the Ethiopian and Nigerian cohorts which exhibited 
some level of heterogeneity. However, TDT and DFAM subphenotype analyses demonstrated 
that rs742071 exhibited over-transmission in NSCL cases in all three populations. In case-
control meta-analyses, VAX1 (rs7078160) was nominally associated with NSCL/P, with 
subpopulation analyses suggesting the two West African countries (largely Ghana) drive this 
signal.  
 Rare variants, but not necessarily common variants, may account for the link between 
certain loci and NSOFCs. We observed many missense and a frameshift mutations in 
sequenced genes. No de novo occurrence was observed for any of these variants due to 
unavailability of some parental samples. Moreover, some of the novel variants were also 
observed in some clinically unaffected parents and controls. We sequenced the novel variants 
in 96 controls from Ghana and the likelihood of identifying these novel variants in more controls 
(i.e. >96) is possible. Nonetheless, these variants are absent in over 1000 individuals in 
1000genomes database (with over 300 Africans), over 61,000 individuals in ExAC database as 
well as 6500 individuals in EVS. There is also the need to functionally validate the pathogenicity 
or otherwise of these variants in vivo. Rare variants in ARHGAP29 (Leslie et al. 2012), PAX7 
and VAX1 (Butali et al. 2013; Leslie et al. 2015), BMP4 (Suzuki et al. 2009), FOXE1 (Moreno et 
al. 2009), MAFB (Butali et al. 2014b) and MSX1 (Liang et al. 2012) have been observed in 
NSOFC cases.  
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 The incidence of OFC in Africans is much lower than in Europeans and Asians (Mossey 
and Modell, 2012; Butali et al. 2014a), even though these populations may share the same or 
similar genetic susceptibility loci for OFCs, as observed in the present study. Though under-
ascertainment due to lack of birth defect registries in most African countries could contribute to 
the low incidence (Butali et al. 2014a), the low incidence of OFCs among Africans may be real, 
as African-derived populations in the Caribbean have lower OFC incidence that is similar to their 
ancestral population (Mossey and Modell, 2012).  We therefore hypothesize the possible 
existence of genetic protective variants in the African genome, whose “rescue mission” reduces 
clefting. The identification and elucidation of such protective variants can be translated 




 The present study has shown evidence of association of certain loci with NSOFCs at 
both nominal and threshold significance. For instance, we have for the first time shown that the 
8q.24 locus is a risk locus in Africans. Our study has thus corroborated earlier suggestion that 
the 8q24 locus may be a risk locus for NSCL/P across major ethnicities, though the effect size is 
smaller in Asians due to lower MAF. Subphenotype as well as sub-population analyses and 
genotyping of other SNPs, other than those already reported for some loci, may be crucial in 
identifying NSOFC loci in various ethnicities and populations. We have also demonstrated the 
existence of rare variants, both novel and known ones, in NSOFC cases from Africa. In 
conclusion, we have for the first time demonstrated associations between the SNPs we studied 
and NSOFC among Africans. Our study is crucial for understanding the genetic architecture of 
NSOFCs in Africans and further suggests the need to carry out GWAS and WGS for every 
ethnicity as far as complex traits are concerned.  
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Table 1: Subphenotypes, gender and sample types of study cohort that passed quality control 
checks and were included in statistical analyses  




Ghana Ethiopia Nigeria 
Case control cohort 
NSCL 162 101 77 340 
NSCLP 144 143 74 361 
NSCPO 102 21 40 163 
Unrelated Controls 408 357 313 1078 
  Case-parents trios 
NSCL 52 2 20 74 
NSCLP 48 3 26 77 
NSCPO 34 1 7 42 
  Case-parent dyads 
NSCL 77 84 51 212 
NSCLP 76 134 47 257 
NSCPO 53 20 32 105 
  other trios  
NSCL 18 0 0 18 
NSCLP 14 0 0 14 
NSCPO 11 0 0 11 
  other dyads 
NSCL 8 0 0 8 
NSCLP 3 0 0 3 
NSCPO 3 0 0 3 
  Singletons 
NSCL 5 13 6 24 
NSCLP 1 8 1 10 
NSCPO 2 0 1 3 
  Tetrads 
NSCLP 2 0 0 2 
  Pentads 
NSCLP 1 0 0 1 
Case probands consisted of   423 males and 441 females whereas unrelated controls were 
made up of 441 males and 637 females. The probands in the case-control arm of the study are 
the same probands in the family-based studies. In some of the designated singletons, parental 
samples failed data cleaning and were dropped from statistical analyses, hence the designation 
of such families as singletons. Singletons were informative in the case-control arm of our study 
but not the family-based studies. Tetrads and pentads were collected from families where two 
individuals were affected with clefts. “Other trios and dyads” largely refers to case-mother-
maternal grandmother trios, case-mother-sibling trios as well as case-siblings trios and dyads. 
Case-parent trios, tetrads and pentads were employed in Transmission Disequilibrium Test 
(TDT) whereas all sample types, except singletons and unrelated controls, were used for 
Family-Based Association for Disease Traits (DFAM) analyses. Only case probands and 
unrelated controls were included in the case-control analyses. 
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Table 2: Meta-analyses of the case-control cohorts from Ghana, Ethiopia and Nigeria 









p OR I p OR I 
rs1801131 MTHFR C/Ar 0.15 0.32 1.08 0.00 0.19 0.79 0.00 
rs1801133 MTHFR A/Gp 0.09 0.49 1.08 18.19 0.44 0.83 0.00 
rs766325 PAX7 G/Ac,d,r 0.18 0.29 0.92 0.00 0.23 0.82 0.00 
rs742071 PAX7 T/Gr 0.39 5.10E-03
f 1.19 54.68 0.76 0.96 0.00 
rs560426 ABCA4 C/Tb,r 0.49 0.10 0.90 6.15 0.16 1.18 0.00 
rs481931 ABCA4 T/Gp 0.10 0.40 1.09 11.13 0.49 0.85 0.00 
rs4147811 ABCA4 T/Cp 0.11 0.23 1.13 67.35 0.93 1.02 0.00 
rs138751793 ARHGAP29 C/Te 0.02 0.24 1.32 0.00 0.47 1.34 27.90 
rs6677101 SLC25A24 G/Tb,d,r 0.33 0.80 0.98 12.11 0.87 1.02 53.89 
rs861020 IRF6 A/Gr 0.11 0.23 1.11 0.00 0.83 0.96 24.15 
rs34743335 IRF6 T/A 0.02 0.59 0.90 0.00 0.84 0.89 38.34 
rs642961 IRF6 A/Gr 0.09 0.32 1.11 68.47 0.57 0.88 44.17 
rs7590268 THADA G/Tr 0.20 0.74 0.98 0.00 0.38 0.87 0.00 
rs4332945 DYSF T/Gb,d,r 0.16 0.94 0.99 0.00 0.97 1.01 0.00 
rs2303596 DYSF T/Cc,d,p 0.22 0.20 0.91 75.32 0.57 1.09 73.54 
rs227782 DYSF A/Gb,r 0.42 0.33 1.06 0.00 0.35 1.12 61.90 
rs115200552 MSX1 C/Ge 0.02 0.38 1.16 28.63 0.01
f 1.81 0.00 





0.62 1.04 0.00 0.68 1.07 0.00 
rs651333 TULP4 C/Tb,c,r 0.34 0.97 1.00 0.00 0.04
f 1.29 0.00 
rs6558002 EPHX2 C/Tb,r 0.24 0.39 1.06 0.00 0.87 1.02 0.00 
rs987525 8q24 A/Cb,r 0.38 1.22E-03
f 0.81 40.55 0.22 0.86 0.00 
rs894673 FOXE1 A/Tp 0.33 0.42 0.95 0.00 0.93 1.01 0.00 
rs3758249 FOXE1 T/Cp 0.33 0.56 0.96 0.00 0.90 1.02 0.00 
rs7078160 VAX1 A/Gr 0.25 0.04
f 1.16 0.00 0.88 1.02 0.00 
rs4752028 VAX1 C/Tb,r 0.45 0.51 0.96 0.00 0.80 0.97 0.00 
rs10785430 ADAMTS20 G/Ar 0.32 0.90 0.99 0.00 0.49 1.09 0.00 
rs9574565 SPRY2 T/Cb,p 0.35 0.75 1.02 0.00 0.45 1.10 0.00 
rs8001641 SPRY2 G/Ab,c,d,p 0.10 0.35 1.08 0.00 0.37 0.85 0.00 
rs17563 BMP4 T/Cb,c,d,r 0.18 0.95 0.99 0.00 0.77 1.04 0.00 
rs1258763 GREM1 C/Tb,c,d,p 0.49 0.11 1.11 0.00 0.50 0.92 0.00 
rs8049367 ADCY9 C/Tc,d,p 0.30 0.20 1.09 0.00 0.10 0.81 0.00 
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rs16260 CDH1 A/Cr 0.13 0.59 1.05 0.00 0.39 0.85 0.00 
rs11642413 CDH1 G/Ab,d,r 0.28 0.83 1.02 0.00 0.21 0.83 0.00 
rs1546124 CRISPLD2 G/Cd,r 0.25 0.60 0.96 0.00 0.89 0.98 0.00 
rs4783099 CRISPLD2 T/Cr 0.33 0.59 1.04 0.00 0.02
f 0.74 0.00 
rs8069536 NTN1 T/Gr 0.32 0.13 1.11 0.97 0.88 0.98 0.00 
rs8081823 NTN1 A/Gp 0.24 0.08 0.88 0.00 0.63 0.94 32.54 
rs17760296 NOG1 G/Tr 0.02 0.92 0.99 0.00 0.04
f 1.74 0.00 
rs227731 NOG1 G/Tb,r 0.22 0.86 0.99 0.00 0.26 1.17 0.00 
rs7224837 AXIN2 G/Ar 0.11 0.75 1.04 0.00 0.81 0.95 0.00 
rs3923086 AXIN2 A/Cb,c,d,r 0.02 0.25 1.15 0.00 NA NA NA 
rs17820943 MAFB T/Cp 0.25 0.33 0.93 15.15 0.68 1.06 22.99 
rs13041247 MAFB C/Tp 0.25 0.37 0.94 34.01 0.42 1.12 0.00 
rs11696257 MAFB T/Cp 0.25 0.30 0.93 32.24 0.61 1.07 0.00 









p OR I p OR I 
rs1801131 MTHFR C/Ar 0.15 0.78 1.03 0.00 0.22 1.13 0.00 
rs1801133 MTHFR A/Gp 0.09 0.71 1.06 8.24 0.30 0.30 0.00 
rs766325 PAX7 G/Ac,d,r 0.18 0.91 0.99 0.00 0.17 0.86 0.00 
rs742071 PAX7 T/Gr 0.39 0.02
f 1.23 68.74 0.03f 1.19 0.00 
rs560426 ABCA4 C/Tr 0.49 0.73 1.03 0.00 0.03f 1.20 10.33 
rs481931 ABCA4 T/Gp 0.10 0.81 0.97 0.00 0.08 1.27 63.75 
rs4147811 ABCA4 T/Cp 0.11 0.50 1.10 65.82 0.15 1.21 15.35 
rs138751793 ARHGAP29 C/Te 0.02 0.19 1.53 66.38 0.41 1.29 0.00 
rs6677101 SLC25A24 G/Tb,d,r 0.33 0.92 0.99 0.00 0.98 1.00 58.97 
rs861020 IRF6 A/Gr 0.11 0.18 1.17 17.72 0.57 1.07 0.00 
rs34743335 IRF6 T/A 0.02 0.87 0.96 0.00 0.50 0.85 23.72 
rs642961 IRF6 A/Gr 0.09 0.96 0.99 15.60 0.15 1.21 62.97 
rs7590268 THADA G/Tr 0.20 0.45 0.92 0.00 0.50 1.07 0.00 
rs4332945 DYSF T/Gb,d,r 0.16 0.54 0.94 10.40 0.71 1.04 0.00 
rs2303596 DYSF T/Cc,d,p 0.22 0.29 0.89 63.58 0.44 0.93 75.54 
rs227782 DYSF A/Gb, r 0.42 0.85 0.98 0.00 0.13 1.14 0.00 
rs115200552 MSX1 C/Ge 0.02 0.18 1.37 61.30 0.68 1.10 0.00 





0.06 1.22 0.00 
0.42 0.91 0.00 
rs651333 TULP4 C/Tb,c,r 0.34 0.63 0.96 0.00 0.74 0.97 0.00 
rs6558002 EPHX2 C/Tb,r 0.24 0.82 1.02 0.00 0.11 0.11 0.00 
rs987525 8q24 A/Cb,r 0.38 5.38E-03
f 1.28 0.00 0.01f 0.80 54.21 
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rs894673 FOXE1 A/Tp 0.33 0.54 0.95 42.39 0.45 0.94 0.00 
rs3758249 FOXE1 T/Cp 0.33 0.53 0.94 46.73 0.68 0.96 0.00 
rs7078160 VAX1 A/Gr 0.25 0.03
f 1.23 0.00 0.20 1.13 24.04 
rs4752028 VAX1 C/Tb,r 0.45 0.55 1.05 16.64 0.50 0.95 0.00 
rs10785430 ADAMTS20 G/Ar 0.32 0.88 1.01 41.30 0.86 0.98 3.00 
rs9574565 SPRY2 T/Cb,p 0.35 0.53 1.06 72.62 0.43 1.07 65.44 
rs8001641 SPRY2 G/Ab,c,d,p 0.10 0.99 1.00 0.00 0.26 1.13 0.00 
rs17563 BMP4 A/Gb,c,d,r 0.18 0.89 0.99 25.84 0.98 1.00 0.00 
rs1258763 GREM1 C/Tb,c,d,p 0.49 0.22 0.90 0.00 0.10 1.15 0.00 
rs8049367 ADCY9 C/Tc,d,p 0.30 0.36 1.09 10.19 0.35 1.08 0.00 
rs16260 CDH1 A/Cr 0.13 0.46 0.91 10.51 0.20 1.16 0.00 
rs11642413 CDH1 G/Ab,d,r 0.28 0.98 1.00 0.00 0.55 1.05 0.00 
rs1546124 CRISPLD2 G/Cd,r 0.25 0.26 0.90 0.00 0.88 1.01 0.00 
rs4783099 CRISPLD2 T/Cr 0.33 0.85 1.02 0.00 0.32 1.09 0.00 
rs8069536 NTN1 T/Gr 0.32 0.72 1.03 3.47 0.04f 1.20 0.00 
rs8081823 NTN1 A/Gp 0.24 0.55 0.95 0.00 0.05 0.83 0.00 
rs17760296 NOG1 G/Tr 0.02 0.83 1.04 5.85 0.85 0.97 0.00 
rs227731 NOG1 G/Tb,r 0.22 0.38 0.92 0.00 0.59 1.05 0.00 
rs7224837 AXIN2 G/Ar 0.11 0.61 1.08 0.00 0.81 1.04 0.00 
rs3923086 AXIN2 A/Cb,c,d,r 0.02 0.62 1.10 40.28 NA NA 0.00 
rs17820943 MAFB T/Cp 0.25 0.25 0.89 15.55 0.43 0.93 0.00 
rs13041247 MAFB C/Tp 0.25 0.25 0.89 31.03 0.54 0.94 0.00 
rs11696257 MAFB T/Cp 0.25 0.24 0.89 27.17 0.40 0.92 0.00 
aThe first allele is the minor allele in Europeans and unless otherwise indicated, the first allele is 
also the minor allele in Europeans, East Asians, South Asians and Africans, bthe first allele is 
the major allele while the second allele is the minor allele in Africans, cthe first allele is the major 
allele while the second allele is the minor allele in South Asians, dthe first allele is the major 
allele while the second allele is the minor allele in East Asians, efirst allele is the minor allele and 
the variation exists only in Africans, floci that reached nominal significance in meta-analyses, 
rminor allele was the risk allele in initial study, pminor allele was protective in initial study, MAF: 
minor allele frequency, p: p-values, OR: odds ratio, I: test of heterogeneity of which 0 to 40 
represents no heterogeneity; NA: not applicable. All p-values reported are for the minor alleles. 
All initial studies were either carried out in Asians and/or Caucasians, but not Africans. Source 
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Table 3: Transmission disequilibrium test (TDT) for case-parent trios only 
 





T/NT p OR (95% CI) T/NT p OR (95% CI) 
rs1801131 MTHFR 27/34 0.37 0.79 (0.48 - 1.32) 10/9 0.82 1.11 (0.45 - 2.73) 
rs1801133 MTHFR 22/23 0.88 0.96 (0.53 - 1.72) 6/8 0.59 0.75 (0.26 - 2.16) 
rs766325 PAX7 43/52 0.36 0.83 (0.55 - 1.24) 11/11 1.00 1.00 (0.43 - 2.31) 
rs742071 PAX7 82/75 0.58 1.09 (0.80 - 1.50)  16/11 0.34 1.46 (0.68 - 3.13) 
rs560426 ABCA4 78/59 0.10 1.32 (0.94 - 1.85) 18/18 1.00 1.00 (0.52 - 1.92) 
rs481931 ABCA4 28/25 0.68 1.12 (0.65 - 1.92) 3/8 0.13 0.38 (0.10 - 1.41) 
rs4147811 ABCA4 26/25 0.89 1.04 (0.60 - 1.80) 5/10 0.20 0.50 (0.17 - 1.46) 
rs138751793 ARHGAP29 5/7 0.56 0.71 (0.23 - 2.25) 1/2 0.56 0.50 (0.05 - 5.51) 
rs6677101 SLC25A24 65/75 0.40 0.87 (0.62 - 1.21) 21/14 0.24 1.50 (0.76 - 2.95) 
rs861020 IRF6 35/29 0.45 1.21 (0.74 - 1.97) 3/7 0.21 0.43 (0.11 - 1.66)  
rs34743335 IRF6 4/2 0.41 2.00 (0.37 - 10.92) 0/0 NA NA (NA) 
rs642961 IRF6 29/29 1.00 1.00 (0.60 - 1.67) 2/7 0.10 0.29 (0.06 - 1.38) 
rs7590268 THADA 49/48 0.92 1.02 (0.69 - 1.52) 8/8 1.00 1.00 (0.38 - 2.66) 
rs4332945 DYSF 43/40 0.74 1.08 (0.70 - 1.65) 11/8 0.49 1.38 (0.55 - 3.42) 
rs2303596 DYSF 45/57 0.23 0.79 (0.53 - 1.18) 12/8 0.37 1.50 (0.61 - 3.67) 
rs227782 DYSF 73/65 0.50 1.12 (0.80 - 1.57) 20/13 0.22 1.54 (0.77 - 3.09) 
rs115200552 MSX1 10/13 0.53 0.77 (0.34 - 1.75) 7/2 0.10 3.50 (0.72 - 16.85) 
rs12532 MSX1 77/71 0.62 1.09 (0.79 - 1.50) 20/22 0.76 0.91 (0.50 - 1.67) 
rs2674394 Gene Desert 40/44 0.66 0.91 (0.59 - 1.40) 9/9 1.00 1.00 (0.40 - 2.52) 
rs651333 TULP4 56/59 0.78 0.95 (0.66 - 1.37)  21/16 0.41 1.31 (0.68 - 2.52) 
rs6558002 EPHX2 47/40 0.45 1.18 (0.77 - 1.79)  13/12 0.84 1.08 (0.49 - 2.37) 
rs987525 8q24 71/59 0.29 1.20 (0.85 - 1.70)  19/20 0.87 0.95 (0.51 - 1.78) 
rs894673 FOXE1 60/67 0.53 0.90 (0.63 - 1.29) 16/15 0.86 1.07 (0.53 - 2.16) 
rs3758249 FOXE1 59/66 0.53 0.89 (0.63 - 1.27) 16/15 0.86 1.07 (0.53 - 2.16) 
rs7078160 VAX1 60/44 0.12 1.36 (0.92 - 2.01) 18/10 0.13 1.80 (0.83 - 3.90) 
rs4752028 VAX1 73/76 0.81 0.96 (0.70 - 1.32) 27/13 0.03b 2.08 (1.07 - 4.03) 
rs10785430 ADAMTS20 61/59 0.86 1.03 (0.72 - 1.48) 15/11 0.43 1.36 (0.63 - 2.97) 
rs9574565 SPRY2 69/55 0.21 1.26 (0.88 - 1.79) 18/17 0.87 1.06 (0.55 - 2.05) 
rs8001641 SPRY2 22/22 1.00 1.00 (0.55 - 1.81) 9/6 0.44 1.50 (0.53 - 4.21) 
rs17563 BMP4 44/44 1.00 1.00 (0.66 - 1.52) 10/15 0.32 0.67 (0.30 - 1.48) 
rs1258763 GREM1 73/58 0.19 1.26 (0.89 - 1.78) 19/21 0.75 0.90 (0.49 - 1.68) 
rs8049367 ADCY9 67/67 1.00 1.00 (0.71 - 1.40) 12/13 0.84 0.92 (0.42 - 2.02) 
rs16260 CDH1 31/28 0.70 1.11 (0.66 - 1.85) 6/13 0.11 0.46 (0.18 - 1.21) 
rs11642413 CDH1 62/49 0.22 1.27 (0.87 - 1.84) 14/11 0.55 1.27 (0.58 - 2.80) 
rs1546124 CRISPLD2 53/44 0.36 1.21 (0.81 - 1.80) 9/14 0.30 0.64 (0.28 - 1.49) 
rs4783099 CRISPLD2 75/64 0.35 1.17 (0.84 - 1.64) 15/21 0.32 0.71 (0.37 - 1.39) 
rs8069536 NTN1 67/70 0.80 0.96 (0.68 - 1.34) 14/13 0.85 1.08 (0.51 - 2.29) 
rs8081823 NTN1 58/56 0.85 1.04 (0.72 - 1.50) 14/15 0.85 0.93 (0.45 - 1.93) 
rs17760296 NOG1 7/8 0.80 0.88 (0.32 - 2.41) 2/0 0.16 NA (NA) 
rs227731 NOG1 47/49 0.84 0.96 (0.64 - 1.43) 20/11 0.11 1.82 (0.87 - 3.80) 
rs7224837 AXIN2 19/27 0.24 0.70 (0.39 - 1.27) 1/6 0.06 0.17 (0.02 - 1.38) 
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rs3923086 AXIN2 2/3 0.65 0.67 (0.11 - 3.99) 1/0 0.32 NA (NA) 
rs17820943 MAFB 49/42 0.46 1.17 (0.77 - 1.76) 15/12 0.56 1.25 (0.59 - 2.67) 
rs13041247 MAFB 49/43 0.53 1.14 (0.76 - 1.72)  15/12 0.56 1.25 (0.59 - 2.67) 
rs11696257 MAFB 48/43 0.60 1.12 (0.74 - 1.69) 14/12 0.69 1.17 (0.54 - 2.52) 





T/NT p OR (95% CI) T/NT p OR (95% CI) 
rs1801131 MTHFR 9/20 0.04b 0.45 (0.20 - 0.99) 18/14 0.48 1.29 (0.64 - 2.59) 
rs1801133 MTHFR 7/8 0.80 0.88 (0.31 - 2.41) 15/15 1.00 1.00 (0.49 - 2.05) 
rs766325 PAX7 18/24 0.35 0.75 (0.41 - 1.38) 25/28 0.68 0.89 (0.52 - 1.53) 
rs742071 PAX7 50/30 0.03b 1.67 (1.06 - 2.62) 32/45 0.14 0.71 (0.45 - 1.12) 
rs560426 ABCA4 32/35 0.71 0.91 (0.57 - 1.48) 46/24 8.55E-03b 1.92 (1.17 - 3.14) 
rs481931 ABCA4 10/13 0.53 0.77 (0.34 - 1.75) 18/12 0.27 1.50 (0.72 - 3.14) 
rs4147811 ABCA4 8/10 0.64 0.80 (0.32 - 2.03) 18/15 0.60 1.20 (0.60 - 2.38) 
rs138751793 ARHGAP29 1/2 0.56 0.50 (0.05 - 5.51) 4/5 0.74 0.80 (0.21 - 2.98) 
rs6677101 SLC25A24 26/41 0.07 0.63 (0.39 - 1.04) 39/34 0.56 1.15 (0.72 - 1.82) 
rs861020 IRF6 20/14 0.30 1.43 (0.72 - 2.83) 15/15 1.00 1.00 (0.49 - 2.05) 
rs34743335 IRF6 2/1 0.56 2.00 (0.18 - 22.06)  2/1 0.56 2.00 (0.18 - 22.06) 
rs642961 IRF6 16/15 0.86 1.07 (0.53 - 2.16) 13/14 0.85 0.93 (0.44 - 1.98) 
rs7590268 THADA 21/32 0.13 0.66 (0.38 - 1.14) 28/16 0.07 1.75 (0.95 - 3.23) 
rs4332945 DYSF 21/17 0.52 1.24 (0.65 - 2.34) 22/23 0.88 0.96 (0.53 - 1.72) 
rs2303596 DYSF 18/22 0.53 0.82 (0.44 - 1.53) 27/35 0.31 0.77 (0.47 - 1.27) 
rs227782 DYSF 33/28 0.52 1.18 (0.71 - 1.95) 40/37 0.73 1.08 (0.69 - 1.69) 
rs115200552 MSX1 6/3 0.32 2.00 (0.50 - 8.00) 4/10 0.11 0.40 (0.13 - 1.28) 
rs12532 MSX1 39/32 0.41 1.22 (0.76 - 1.95) 38/39 0.91 0.97 (0.62 - 1.52) 
rs2674394 Gene Desert 21/17 0.52 1.24 (0.65 - 2.34) 19/27 0.24 0.70 (0.39 - 1.27) 
rs651333 TULP4 26/26 1.00 1.00 (0.58 - 1.72) 30/33 0.71 0.91 (0.55 - 1.49) 
rs6558002 EPHX2 15/18 0.60 0.83 (0.42 - 1.65) 32/22 0.17 1.46 (0.85 - 2.50) 
rs987525 8q24 35/28 0.38 1.25 (0.76 - 2.06) 36/31 0.54 1.16 (0.72 - 1.88) 
rs894673 FOXE1 27/31 0.60 0.87 (0.52 - 1.46) 33/36 0.72 0.92 (0.57 - 1.47) 
rs3758249 FOXE1 27/31 0.60 0.87 (0.52 - 1.46) 32/35 0.71 0.91 (0.57 - 1.48) 
rs7078160 VAX1 37/23 0.07 1.61 (0.96 - 2.71) 23/21 0.76 1.10 (0.61 - 1.98) 
rs4752028 VAX1 32/38 0.47 0.84 (0.53 - 1.35) 41/38 0.74 1.08 (0.69 - 1.68) 
rs10785430 ADAMTS20 25/28 0.68 0.89 (0.52 - 1.53) 36/31 0.54 1.16 (0.72 - 1.88) 
rs9574565 SPRY2 35/29 0.45 1.21 (0.74 - 1.97) 34/26 0.30 1.31 (0.78 - 2.18) 
rs8001641 SPRY2 12/12 1.00 1.00 (0.45 - 2.27) 10/10 1.00 1.00 (0.42 - 2.40) 
rs17563 BMP4 22/16 0.33 1.38 (0.72 - 2.62) 22/28 0.40 0.79 (0.45 - 1.37) 
rs1258763 GREM1 31/27 0.60 1.15 (0.69 - 1.92) 42/31 0.20 1.36 (0.85 - 2.16) 
rs8049367 ADCY9 25/28 0.68 0.89 (0.52 - 1.53) 42/39 0.74 1.08 (0.70 - 1.67) 
rs16260 CDH1 12/14 0.69 0.86 (0.40 - 1.85) 19/14 0.38 1.36 (0.68 - 2.71) 
rs11642413 CDH1 25/22 0.66 1.14 (0.64 - 2.02) 37/27 0.21 1.37 (0.83 - 2.25) 
rs1546124 CRISPLD2 25/22 0.66 1.14 (0.61 - 2.02) 28/22 0.40 1.27 (0.73 - 2.23) 
rs4783099 CRISPLD2 39/35 0.64 1.11 (0.71 - 1.76) 36/29 0.39 1.24 (0.76 - 2.02) 
rs8069536 NTN1 32/35 0.71 0.91 (0.57 - 1.48) 35/35 1.00 1.00 (0.63 - 1.60) 
rs8081823 NTN1 30/20 0.16 1.50 (0.85 - 2.64) 28/36 0.32 0.78 (0.47 - 1.27) 
rs17760296 NOG1 5/2 0.26 2.50 (0.49 - 12.89) 2/6 0.16 0.33 (0.07 - 1.65) 
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rs227731 NOG1 22/26 0.56 0.85 (0.48 - 1.49) 25/23 0.77 1.09 (0.62 - 1.92) 
rs7224837 AXIN2 10/9 0.82 1.11 (0.45 - 2.73) 9/18 0.08 0.50 (0.22 - 1.11) 
rs3923086 AXIN2 1/2 0.56 0.50 (0.05 - 5.51) 1/1 1.00 1.00 (0.06 - 15.99) 
rs17820943 MAFB 18/22 0.53 0.82 (0.44 - 1.53) 31/20 0.12 1.55 (0.88 - 2.72) 
rs13041247 MAFB 18/22 0.53 0.82 (0.44 - 1.53) 31/21 0.17 1.48 (0.85 - 2.57) 
rs11696257 MAFB 18/22 0.53 0.82 (0.44 - 1.53) 30/21 0.21 1.43 (0.82 - 2.50) 
bLoci that demonstrated over-transmission at threshold significance of p≤0.05, OR: Odds ratio, CI: 
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Table 4: Family-Based Association for Disease Traits (DFAM) for cases and relatives 
SNP Gene/Loci 
p-values 
NSCL/P NSCL NSCLP NSCPO 
rs1801131 MTHFR 0.70 0.68 0.24 0.67 
rs1801133 MTHFR 0.82 0.51 0.59 0.29 
rs766325 PAX7 0.61 0.71 0.74 0.24 
rs742071 PAX7 0.32 0.02b 0.29 0.96 
rs560426 ABCA4 2.59E-02b 0.72 4.75E-03b 0.80 
rs481931 ABCA4 0.15 0.55 0.16 0.61 
rs4147811 ABCA4 0.29 0.44 0.48 0.51 
rs138751793 ARHGAP29 0.38 0.66 0.43 0.40 
rs6677101 SLC25A24 1.00 0.80 0.64 0.24 
rs861020 IRF6 0.43 0.23 0.98 0.35 
rs34743335 IRF6 0.32 0.52 0.47 0.61 
rs642961 IRF6 0.83 0.99 0.98 0.15 
rs11119388 SYT14 0.83 0.85 0.92 0.91 
rs7590268 THADA 0.85 0.30 0.18 0.77 
rs4332945 DYSF 0.04b 0.02b 0.60 0.62 
rs2303596 DYSF 0.81 0.84 0.53 0.60 
rs227782 DYSF 0.36 0.48 0.55 0.47 
rs115200552 MSX1 0.89 0.13 3.50E-02b 0.08 
rs12532 MSX1 0.67 0.96 0.30 0.43 
rs2674394 Gene Desert 0.59 0.11 0.58 0.51 
rs651333 TULP4 0.92 0.90 0.63 0.20 
rs6558002 EPHX2 0.38 0.77 0.27 0.52 
rs987525 8q24 0.80 0.50 0.52 0.99 
rs894673 FOXE1 0.69 0.88 0.46 0.55 
rs3758249 FOXE1 0.69 0.86 0.46 0.55 
rs7078160 VAX1 0.21 0.18 0.77 0.28 
rs4752028 VAX1 0.88 0.44 0.30 0.06 
rs10785430 ADAMTS20 0.84 0.86 0.62 0.66 
rs9574565 SPRY2 0.07 0.16 0.28 0.22 
rs8001641 SPRY2 0.32 0.19 0.88 0.64 
rs375489721 MIR17HG NA NA NA NA 
rs185831554 MIR17HG 0.32 0.32 NA NA 
rs17563 BMP4 0.66 0.15 0.80 0.70 
rs1258763 GREM1 0.14 1.00 0.06 0.98 
rs8049367 ADCY9 0.23 0.24 0.56 0.18 
rs16260 CDH1 0.59 0.59 0.36 0.46 
rs11642413 CDH1 0.33 0.81 0.08 0.88 
rs1546124 CRISPLD2 0.30 0.53 0.45 0.15 
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rs4783099 CRISPLD2 0.17 0.14 0.89 0.37 
rs8069536 NTN1 0.58 0.47 0.87 0.23 
rs8081823 NTN1 0.97 0.30 0.19 0.89 
rs17760296 NOG1 0.63 0.25 0.97 0.63 
rs227731 NOG1 0.24 0.41 0.43 0.09 
rs7224837 AXIN2 0.20 0.75 0.12 0.35 
rs3923086 AXIN2 0.89 0.70 2.88E-03b 0.85 
rs17820943 MAFB 0.31 0.88 0.14 0.65 
rs13041247 MAFB 0.37 0.83 0.21 0.63 
rs11696257 MAFB 0.46 0.89 0.26 0.77 
bLoci that demonstrated over-transmission at threshold significance, NA: not applicable. 
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Table 5: Novel, rare and potentially aetiologic variants observed in sequenced genes 
Part A: Variants observed in cases and some parents but not in controls 









c.341-30T>A N/A 1 NSCL N/A 
c.511-107T>C N/A 2 NSCLP  and 
NSCPO 
N/A 
c.967A>G p.Asn323Asp 1 NSCL Absent in father 
c.1277delAinsTA p.Lys426IlefsTer6 1 NSCLP Absent in mother 
c.1281+4A>G N/A 1 NSCLP Observed in clinically 
unaffected mother 
PAX7 
c.1227G>A p.Leu409Leu 1 NSCL N/A 
Part B: Bioinformatics-predicted effects of potentially pathogenic variants 




c.341-30T>A N/A N/A Alteration of ESS 
site 
N/A 
c.511-107T>C N/A N/A Alteration of ESS 
site and creation 
of new ESE site 
N/A 
c.967A>G Benign Deleterious N/A N/A 
c.1277delAinsTA N/A N/A N/A N/A 
c.1281+4A>G N/A N/A Alteration of 
wildtype donor site 
N/A 
PAX7 
c.1227G>A Benign Tolerated Alteration of an 
ESE site 
N/A 
 ESS: Exonic Splicing Silencer, ESE: Exonic Splicing Enhancer, N/A: Not Applicable, NSCLP: 
nonsyndromic cleft lip and palate, NSCL: nonsyndromic cleft lip only, NSCPO: nonsyndromic 
cleft palate only. All analyses were based on genome assembly number GRCh37/hg19, 2009 
(http://genome.ucsc.edu). 
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Eligible subjects or participants 
Eligible subjects were individuals with NSOFCs and their families, born to indigenous 
Ghanaian, Ethiopian and Nigerian parents. These families were recruited at the cleft clinics and 
during surgical missions. Births from Caucasians and Asians were excluded. Controls were 
recruited in Ghana, Nigeria and Ethiopia at the immunization clinics and dental clinics to match 
cases recruited from each of these countries. Controls were Africans born alive without any 
congenital birth defects in Ghana, Ethiopia and Nigeria. In Nigeria, two different centers (Lagos 
and Ife) coordinated patient recruitment. Only one center each coordinated patient recruitment 
in Ghana and Ethiopia. We have previously described individuals that are involved in 
recruitments for our cleft studies in Africa (Butali et al. 2011; Butali et al. 2015). In summary, 
recruitment is done by surgeons (i.e. plastic surgery, ear nose and throat surgeons, pediatric 
surgeons, maxillofacial surgeons and dental surgeons). 
 
DNA Collection and processing 
We collected saliva and cheek swab samples from participants using Oragene DNA 
Collection Kits (http://www.dnagenotek.com). We extracted DNA from both saliva and cheek 
swab samples using the Oragene Saliva processing protocol 
(http://genetics.uiowa.edu/protocols.php). We then determined the concentration of DNA using 
Quibit Assay that employed Quibit 2.0 Fluorometer 
(http://www.invitrogen.com/site/us/en/home/brands/Product-Brand/Qubit.html). We finally 
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The detailed protocol is available at Murray Laboratory 
(http://genetics.uiowa.edu/protocols.php) but a summary is presented here. We selected these 
SNPs based on GWAS and candidate gene studies. We randomly assigned each sample to a 
well in a labeled 96-well microplate to form a Plate Map, using sample concentration of 2ng/ul. 
Each of these microplates also contained two template controls, NA18856 (male) and NA18855 
(female). These two template controls are Yoruba HapMap samples. They therefore served as a 
guide in calling the genotype of individuals genotyped in this study. Each microplate also had 
provision for at least two No Template Controls (NTCs), which was dH2O; however, NTCs were 
not added unto Microplates until the running of the chips. SNPs were designed based on human 
genome assembly GRCh37/hg19, 2009 (http://genome.ucsc.edu) and were obtained from 
ABi/Life Technologies (www.lifetechnologies.com). 
 
DNA sequencing and DNA sequence analyses 
The protocols for primer design and optimization as well as DNA amplification by PCR 
and electrophoresis have been described earlier (Butali et al. 2014). We shipped PCR products 
to Functional Biosciences, Madison, Wisconsin (http://order.functionalbio.com/seq/index) where 
they were sequenced using an ABI 3730XL 
(http://www.appliedbiosystems.com/absite/us/en/home.html). Chromatograms were then 
transferred to a Unix workstation, base-called with PHRED 
(http://www.phrap.org/phredphrapconsed.html, v.0.961028), assembled with PHRAP 
(http://www.phrap.org/, v.0.960731), scanned by POLYPHRED 
(http://droog.gs.washington.edu/polyphred/, v. 0.970312) and viewed with CONSED programme 
(http://www.phrap.org/consed/consed.html, v. 4.0). 
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 We ascertained the genomic location of each variant revealed by CONSED by 
employing the “Blat” function of UCSC Genome Browser (https://genome.ucsc.edu/). We 
predicted the functional effect of a coding variant on protein using Polyphen-2 
(http://genetics.bwh.harvard.edu/pph2/), SIFT (http://sift.jcvi.org/) and Ensemble 
(http://www.ensembl.org/Homo_sapiens/Tools/VEP). Effect of a variant on mRNA splicing was 
ascertained using Human Splicing Finder 3.0 (http://www.umd.be/HSF3/). Finally, we predicted 
the effect of a mutation on a regulatory region using RegulomeDB (http://regulomedb.org/).  
We ascertained the Minor Allele Frequencies (MAF) or novelty of a mutation by 
comparing it to variants in 1000 Genomes (http://browser.1000genomes.org/index.html), Exome 
Variant Server (http://evs.gs.washington.edu/EVS/), dbSNP (www.ncbi.nlm.nih.gov/SNP/), 
ExAC Browser (http://exac.broadinstitute.org/) and other literature on OFCs. We classified 
mutations as “novel” if they have never been reported in any of these databases or literature. 
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Table S1: List of 48 SNPs that were genotyped 





























1 18956458 rs766325 PAX7 A>G A/A A/A 99.6 




1 18979874 rs742071 PAX7 G>T T/G G/G 99.4 




1 94553438 rs560426 ABCA4 T>C C/T T/C 99.5 




1 94570016 rs481931 ABCA4 G>T G/G No data 99.5 




1 94575056 rs4147811 ABCA4 C>T C/C No data 99.3 




1 94650805 rs138751793 ARHGAP29 T>C T/T No data 99.3 Present Study Africans 
1 108699730 rs6677101 SLC25A24 T>G G/T G/G 99.1 
Butler et al. 
2015 
Europeans 




1 209979529 rs34743335 IRF6 A>T A/A No data 97.9 
Pegelow et al. 
2008 
Europeans 
1 209989270 rs642961 IRF6 G>A G/G G/G 99.5 




1 210174417 rs11119388 SYT14 A>G A/A A/A 99.6 




2 43540125 rs7590268 THADA T>G T/T T/T 99.5 
Mangold et al. 
2010 
Europeans 
2 71674476 rs4332945 DYSF T>G T/T T/T 99.3 
Brayton et al. 
2009 
Mouse screen 
2 71780215 rs2303596 DYSF C>T C/T C/C 99.2 
Brayton et al. 
2009 
Mouse screen 
2 71866842 rs227782 DYSF A>G A/G A/G 99.3 
Brayton et al. 
2009 
Mouse screen 
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4 4865146 rs12532 MSX1 A>G G/A A/G 99.4 
Suzuki et al. 
2004 
Asians 
4 4864991 rs115200552 MSX1 G>C G/G No data 99.5 Present study Africans 
6 93506409 rs2674394 Gene Desert A>C C/C C/C 99.4 




6 158885758 rs651333 TULP4 C>T C/T T/T 99.3 




8 27389542 rs6558002 EPHX2 C>T C/C C/C 99.1 




8 129946154 rs987525 8q24 A>C A/A C/C 99.4 
Birnbaum et al. 
2009 
Europeans 
9 100612270 rs894673 FOXE1 A>T T/T T/T 99.3 





9 100614140 rs3758249 FOXE1 T>C C/C C/C 99.4 





10 118827560 rs7078160 VAX1 G>A A/G A/G 99.2 




10 118834991 rs4752028 VAX1 T>C C/C C/T 99.6 




12 43819298 rs10785430 ADAMTS20 A>G A/A A/A 99.5 
Wolf et al. 
2015 
Hispanics 
13 80668874 rs9574565 SPRY2 T>C C/T T/T 99.4 




13 80692811 rs8001641 SPRY2 G>A A/G G/G 99.5 




13 92003297 rs375489721 MIR17HG T>C T/T No data 99.1 
Amendt et al. 
unplished 
Mouse screen 
13 92003356 rs185831554 MIR17HG T>G T/T No data 99.3 
Amendt et al. 
unplished 
Mouse screen 
14 54417522 rs17563 BMP4 A>G A/A G/A 99.5 
Chen et al. 
2008 
Asians 
15 33050423 rs1258763 GREM1 C>T C/C C/C 99.3 




16 3980445 rs8049367 ADCY9 C>T C/T C/T 99.4 Sun et al. 2015 Asians 
16 68771034 rs16260 CDH1 C>A C/A A/C 99.2 
Song et al. 
2011 
Asians 
16 68790394 rs11642413 CDH1 G>A G/G A/G 99.5 
Song et al. 
2011 
Asians 
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Note: Except the studies designated as “present study” and Moreno et al. 2009, these loci were largely associated with NSCL/P in the study populations. 
16 84872051 rs1546124 CRISPLD2 C>G C/C C/G 99.5 
Chiquet et al. 
2007 
Hispanics 
16 84941329 rs4783099 CRISPLD2 C>T C/T C/C 99.3 
Chiquet et al. 
2007 
Hispanics 
17 8956285 rs8069536 NTN1 G>T G/G G/T 99.4 




17 8965551 rs8081823 NTN1 G>A A/G G/G 99.4 




17 54615617 rs17760296 NOG1 T>G T/T T/T 99.5 
Mangold et al. 
2010 
Europeans 
17 54773238 rs227731 NOG1 G>T T/G T/G 99.3 
Mangold et al. 
2010 
Europeans 
17 63528123 rs7224837 AXIN2 A>G A/G A/A 99.3 




17 63549488 rs3923086 AXIN2 A>C A/A A/A 99.7 




20 39268516 rs17820943 MAFB C>T T/C C/C 99.6 




20 39269074 rs13041247 MAFB T>C C/T T/T 99.5 




20 39270816 rs11696257 MAFB C>T T/C C/C 99.3 
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Table S2: Case-control analyses for Ethiopia 





p OR 95% CI p OR 95% CI 
rs1801131 MTHFR 0.37 1.10 0.89 - 1.36 0.88 0.95 0.49 - 1.85 
rs1801133 MTHFR 0.85 0.97 0.71 - 1.34 0.83 0.89 0.31 - 2.54 
rs766325 PAX7 0.39 0.90 0.71 - 1.14 0.86 0.94 0.46 - 1.92 
rs742071 PAX7 5.57E-03a 1.33 1.09 - 1.63 0.53 0.82 0.44 - 1.53 
rs560426 ABCA4 0.95 0.99 0.81 - 1.22 0.23 1.46 0.79 - 2.71 
rs481931 ABCA4 0.75 0.95 0.68 - 1.32 0.03a 0.00 0.00 - NA 
rs4147811 ABCA4 0.69 0.94 0.67 - 1.30 0.03a 0.00 0.00 - NA 
rs138751793 ARHGAP29 0.62 0.59 0.07 - 4.88 0.05 6.42 0.73 - 56.15  
rs6677101 SLC25A24 0.30 0.89 0.72 - 1.11 0.52 1.23 0.66 - 2.29  
rs861020 IRF6 0.11 1.21 0.96 - 1.52 0.13 1.66 0.86 - 3.19  
rs34743335 IRF6 0.27 0.78 0.51 - 1.21 0.52 0.63 0.15 - 2.63  
rs642961 IRF6 0.02a 1.44 1.07 - 1.94 0.22 1.68 0.73 - 3.84  
rs7590268 THADA 0.47 0.92 0.73 - 1.16 0.70 1.14 0.58 - 2.26  
rs4332945 DYSF 0.45 0.92 0.74 - 1.14 0.77 0.91 0.47 - 1.74  
rs2303596 DYSF 2.31E-03a 0.69 0.54 - 0.87 0.10 0.51 0.22 - 1.15  
rs227782 DYSF 0.10 0.84 0.68 - 1.04 0.09 0.55 0.27 - 1.10  
rs115200552 MSX1 0.40 1.46 0.60 - 3.55 0.33 2.66 0.34 - 20.96  
rs12532 MSX1 0.59 1.06 0.86 - 1.31 0.22 0.65 0.32 - 1.31  
rs2674394 
Gene 
Desert 0.69 0.95 0.74 - 1.23 0.73 1.14 0.54 - 2.41  
rs651333 TULP4 0.52 0.94 0.76 - 1.15 0.70 0.88 0.47 - 1.67  
rs6558002 EPHX2 0.44 0.92 0.76 - 1.13 0.44 0.78 0.42 - 1.46  
rs987525 8q24 7.82E-04a 1.41 1.15 - 1.73 0.20 1.50 0.81 - 2.78  
rs894673 FOXE1 0.47 0.93 0.75 - 1.15 0.53 1.23 0.65 - 2.29 
rs3758249 FOXE1 0.52 0.93 0.75 - 1.16 0.52 1.23 0.66 - 2.30  
rs7078160 VAX1 0.48 1.10 0.85 - 1.41 0.56 0.77 0.32 - 1.86  
rs4752028 VAX1 0.90 0.99 0.81 - 1.21 0.50 0.80 0.42 - 1.52  
rs10785430 ADAMTS20 0.83 1.02 0.82 - 1.27  0.69 1.14 0.59 - 2.19  
rs9574565 SPRY2 0.87 0.98 0.80 - 1.21 0.57 0.83 0.43 - 1.59 
rs8001641 SPRY2 0.21 1.15 0.92 - 1.43 0.19 0.59 0.27 - 1.30 
rs17563 BMP4 0.91 0.99 0.80 - 1.22 0.75 0.90 0.46 - 1.75 
rs1258763 GREM1 0.15 0.86 0.70 - 1.06 0.79 1.09 0.59 - 2.02 
rs8049367 ADCY9 0.95 0.99 0.80 - 1.23 0.36 0.72 0.36 - 1.46 
rs16260 CDH1 0.46 1.11 0.84 - 1.48 0.66 0.81 0.31 - 2.08 
rs11642413 CDH1 0.39 1.09 0.89 - 1.34 0.84 1.07 0.58 - 1.97 
rs1546124 CRISPLD2 0.44 0.92 0.75 - 1.13 0.36 0.74 0.39 - 1.41 
rs4783099 CRISPLD2 0.87 0.98 0.80 - 1.21 0.17 0.62 0.32 - 1.23 
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rs8069536 NTN1 0.77 1.04 0.81 - 1.32 0.15 0.51 0.20 - 1.31 
rs8081823 NTN1 0.20 0.87 0.69 - 1.08 0.04a 0.41 0.17 - 0.98 
rs17760296 NOG1 0.48 0.91 0.70 - 1.18 0.51 1.28 0.62 - 2.63 
rs227731 NOG1 0.45 0.93 0.76 - 1.13 0.71 0.89 0.48 - 1.65 
rs7224837 AXIN2 0.53 1.16 0.73 - 1.85 0.16 0.00 0.00 - NA 
rs3923086 AXIN2 0.42 1.11 0.87 - 1.41 0.59 1.22 0.59 - 2.52 
rs17820943 MAFB 0.06 0.81 0.65 - 1.01 0.27 0.68 0.34 - 1.36 
rs13041247 MAFB 0.04a 0.80 0.64 - 0.99 0.51 0.80 0.41 - 1.55 
rs11696257 MAFB 0.04a 0.79 0.64 - 0.99 0.51 0.80 0.41 - 1.55 





p OR 95% CI p OR 95% CI 
rs1801131 MTHFR 0.37 1.15 0.85 - 1.57 0.57 1.08 0.82 - 1.42 
rs1801133 MTHFR 0.42 0.81 0.49 - 1.34 0.58 1.12 0.75 - 1.66 
rs766325 PAX7 0.68 0.93 0.66 - 1.31 0.56 0.91 0.68 - .123 
rs742071 PAX7 7.74E-03a 1.49 1.11 - 2.00 0.06 1.28 0.99 - 1.65 
rs560426 ABCA4 0.42 0.88 0.66 - 1.19 0.57 1.08 0.83 - 1.40 
rs481931 ABCA4 0.70 0.91 0.56 - 1.49 0.91 1.03 0.67 - 1.56 
rs4147811 ABCA4 0.62 0.88 0.54 - 1.44 0.96 1.01 0.66 - 1.53 
rs138751793 ARHGAP29 0.45 0.00 0.00 - NA 0.94 0.93 0.11 - 7.76 
rs6677101 SLC25A24 0.93 0.99 0.72 - 1.34 0.30 0.87 0.66 - 1.14 
rs861020 IRF6 0.07 1.35 0.98 - 1.87 0.31 1.17 0.87 - 1.57 
rs34743335 IRF6 0.53 0.82 0.44 - 1.53 0.26 0.73 0.42 - 1.27 
rs642961 IRF6 0.49 1.18 0.74 - 1.86 9.11E-03a 1.61 1.12 - 2.31 
rs7590268 THADA 0.17 0.78 0.54 - 1.11 0.98 1.00 0.75 - 1.34 
rs4332945 DYSF 0.14 0.79 0.57 - 1.08 0.96 1.01 0.77 - 1.32 
rs2303596 DYSF 4.99E-03a 0.59 0.41 - 0.86 0.03a 0.70 0.52 - 0.96 
rs227782 DYSF 0.41 0.88 0.65 - 1.19 0.17 0.83 0.63 - 1.09 
rs115200552 MSX1 0.04a 2.81 0.99 - 7.97 0.69 0.74 0.17 - 3.26 
rs12532 MSX1 0.82 1.04 0.76 - 1.41 0.58 1.08 0.83 - 1.41 
rs2674394 
Gene 
Desert 0.70 1.07 0.75 - 1.54 0.60 0.91 0.66 - 1.27 
rs651333 TULP4 0.35 0.86 0.64 - 1.17 0.79 0.96 0.74 - 1.25 
rs6558002 EPHX2 0.79 0.96 0.72  - 1.29 0.35 0.88 0.68 - 1.15 
rs987525 8q24 0.03a 1.38 1.03 - 1.85 1.07E-03a 1.54 1.19 - 1.99 
rs894673 FOXE1 0.17 0.80 0.58 - 1.10 0.99 1.00 0.77 - 1.31 
rs3758249 FOXE1 0.12 0.78 0.56 - 1.07 0.79 1.04 0.79 - 1.36 
rs7078160 VAX1 0.87 0.97 0.66 - 1.43 0.20 1.23 0.89 - 1.68 
rs4752028 VAX1 0.85 0.97 0.72 - 1.31 0.99 1.00 0.77 - 1.30 
rs10785430 ADAMTS20 0.14 1.26 0.93 - 1.72 0.36 0.87 0.66 - 1.16 
rs9574565 SPRY2 7.05E-03a 1.50 1.11 - 2.01 0.02a 0.73 0.55 - 0.95 
rs8001641 SPRY2 0.72 0.94 0.68 - 1.31 0.09 1.27 0.97 - 1.67 
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rs17563 BMP4 0.93 0.99 0.72 - 1.35 0.91 1.02 0.77 - 1.33 
rs1258763 GREM1 0.44 0.89 0.66 - 1.20 0.15 0.82 0.63 - 1.07 
rs8049367 ADCY9 0.69 0.94 0.68 - 1.29 0.81 1.03 0.79 - 1.36 
rs16260 CDH1 0.83 1.05 0.69 - 1.59 0.58 1.11 0.77 - 1.59 
rs11642413 CDH1 0.27 1.18 0.88 - 1.58 0.66 1.06 0.82 - 1.37 
rs1546124 CRISPLD2 0.47 0.90 0.66 - 1.21 0.62 0.94 0.72 - 1.21 
rs4783099 CRISPLD2 0.49 0.90 0.66 - 1.22 0.72 1.05 0.81 - 1.36 
rs8069536 NTN1 0.65 0.92 0.64 - 1.33 0.28 1.18 0.87 - 1.59 
rs8081823 NTN1 0.84 0.97 0.70 - 1.33 0.30 0.86 0.64 - 1.15 
rs17760296 NOG1 0.42 0.85 0.58 - 1.26 0.68 0.93 0.67 - 1.30 
rs227731 NOG1 0.19 0.82 0.61 - 1.10 0.84 0.97 0.75 - 1.26 
rs7224837 AXIN2 0.61 1.19 0.62 - 2.29 0.54 1.20 0.67 - 2.18 
rs3923086 AXIN2 0.79 1.05 0.73 - 1.50 0.19 1.22 0.90 - 1.66 
rs17820943 MAFB 0.02a 0.68 0.48 - 0.95 0.24 0.85 0.64 - 1.12 
rs13041247 MAFB 0.02a 0.67 0.48 - 0.93 0.22 0.84 0.64 - 1.11 
rs11696257 MAFB 0.02a 0.67 0.48 - 0.93 0.19 0.83 0.63 - 1.09 
aLoci that reached nominal significance 
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Table S3: Case-control analyses for Ghana 





p OR 95% CI p OR 95% CI 
rs1801131 MTHFR 0.82 1.03 0.79 - 1.35 0.40 0.81 0.51 - 1.32 
rs1801133 MTHFR 0.94 1.01 0.72 - 1.43 0.51 0.81 0.44 - 1.49 
rs766325 PAX7 0.82 0.97 0.75 - 1.26 0.65 0.91 0.60 - 1.38 
rs742071 PAX7 0.84 1.02 0.85 - 1.23 0.88 0.98 0.72 - 1.33 
rs560426 ABCA4 0.03a 1.22 1.01 - 1.47 0.16 1.24 0.92 - 1.67 
rs481931 ABCA4 0.67 1.07 0.78 - 1.49 0.47 0.81 0.46 - 1.43 
rs4147811 ABCA4 0.89 1.02 0.74 - 1.42 0.64 0.88 0.50 - 1.52 
rs138751793 ARHGAP29 0.77 1.10 0.57 - 2.12 0.68 0.77 0.23 - 2.63 
rs6677101 SLC25A24 0.33 1.10 0.91 - 1.34 0.27 1.19 0.87 - 1.63 
rs861020 IRF6 0.88 0.98 0.72 - 1.32 0.27 0.73 0.41 - 1.28 
rs34743335 IRF6 0.93 1.04 0.43 - 2.50 0.52 0.52 0.07 - 4.07 
rs642961 IRF6 0.48 0.89 0.63 - 1.24 0.13 0.60 0.30 - 1.17 
rs7590268 THADA 0.80 1.03 0.82 - 1.30 0.26 0.79 0.52 - 1.20 
rs4332945 DYSF 0.87 1.02 0.79 - 1.32 0.70 0.92 0.61 - 1.40 
rs2303596 DYSF 0.99 1.00 0.80 - 1.25 0.05 1.40 1.00 - 1.98 
rs227782 DYSF 0.75 1.03 0.85 - 1.25 0.30 1.17 0.87 - 1.59 
rs115200552 MSX1 0.24 1.28 0.85 - 1.91 0.06 1.72 0.97 - 3.03 
rs12532 MSX1 0.33 0.91 0.76 - 1.10 0.87 1.03 0.76 - 1.38 
rs2674394 Gene Desert 0.55 1.08 0.84 - 1.38 0.75 1.07 0.71 - 1.60 
rs651333 TULP4 0.74 0.97 0.79 - 1.18 0.14 1.27 0.93 - 1.73 
rs6558002 EPHX2 0.52 1.08 0.86 - 1.35 0.67 0.92 0.62 - 1.36 
rs987525 8q24 0.11 0.85 0.70 - 1.04 0.80 0.96 0.70 - 1.31 
rs894673 FOXE1 0.24 0.89 0.73 - 1.08 0.56 0.91 0.66 - 1.25 
rs3758249 FOXE1 0.30 0.90 0.74 - 1.10 0.59 0.92 0.67 - 1.26 
rs7078160 VAX1 0.03a 1.25 1.02 - 1.54 0.59 1.10 0.78 - 1.55 
rs4752028 VAX1 0.12 0.86 0.72 - 1.04 0.54 0.91 0.67 - 1.23 
rs10785430 ADAMTS20 0.46 0.93 0.75 - 1.14 0.20 1.23 0.89 - 1.70 
rs9574565 SPRY2 0.45 1.08 0.89 - 1.30 0.47 1.12 0.83 - 1.51 
rs8001641 SPRY2 0.79 1.04 0.78 - 1.40 0.55 0.86 0.53 - 1.41 
rs17563 BMP4 0.45 0.91 0.72 - 1.16 0.99 1.00 0.69 - 1.45 
rs1258763 GREM1 0.63 1.05 0.87 - 1.26 0.65 0.93 0.69 - 1.26 
rs8049367 ADCY9 0.34 1.10 0.90 - 1.34 0.48 0.89 0.64 - 1.23 
rs16260 CDH1 0.84 1.03 0.78 - 1.37 0.46 0.84 0.52 - 1.35 
rs11642413 CDH1 0.81 0.97 0.78 - 1.21 0.24 0.80 0.55 - 1.16 
rs1546124 CRISPLD2 0.92 1.01 0.80 - 1.28 0.44 1.15 0.80 - 1.65 
rs4783099 CRISPLD2 0.41 1.08 0.90 - 1.31 0.28 0.84 0.61 - 1.15 
rs8069536 NTN1 0.70 1.04 0.86 - 1.27 0.88 0.98 0.71 - 1.34 
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rs8081823 NTN1 0.46 0.92 0.75 - 1.14 0.73 1.06 0.76 - 1.47 
rs17760296 NOG1 0.90 1.05 0.48 - 2.28 0.07 2.66 0.90 - 7.87 
rs227731 NOG1 0.43 1.10 0.87 - 1.38 0.25 1.23 0.86 - 1.75 
rs7224837 AXIN2 0.80 1.04 0.75 - 1.44 0.49 0.81 0.44 - 1.48 
rs3923086 AXIN2 0.36 1.99 0.44 - 8.92 0.33 0.00 0.00 - NA 
rs17820943 MAFB 0.88 1.02 0.81 - 1.28 0.82 1.04 0.73 - 1.49 
rs13041247 MAFB 0.70 1.05 0.83 - 1.32 0.58 1.11 0.77 - 1.59 
rs11696257 MAFB 0.84 1.02 0.81 - 1.29 0.88 1.03 0.72 - 1.48 





p OR 95% CI p OR 95% CI 
rs1801131 MTHFR 0.58 0.90 0.63 - 1.30 0.41 1.17 0.81 - 1.68 
rs1801133 MTHFR 0.91 1.03 0.64 - 1.64 0.92 1.02 0.64 - 1.63 
rs766325 PAX7 0.57 1.10 0.79 - 1.53 0.30 0.82 0.57 - 1.19 
rs742071 PAX7 0.83 0.97 0.76 - 1.25 0.48 1.10 0.85 - 1.42 
rs560426 ABCA4 0.38 1.12 0.87 - 1.42 0.01a 1.39 1.08 - 1.80 
rs481931 ABCA4 0.82 1.05 0.68 - 1.62 0.76 1.07 0.69 - 1.67 
rs4147811 ABCA4 0.57 0.88 0.55 - 1.39 0.47 1.17 0.76 - 1.80 
rs138751793 ARHGAP29 0.54 0.71 0.24 - 2.09 0.36 1.43 0.66 - 3.09 
rs6677101 SLC25A24 0.98 1.00 0.77 - 1.31 0.09 1.26 0.97 - 1.65 
rs861020 IRF6 0.73 1.07 0.73 - 1.57 0.62 0.90 0.58 -1 .38 
rs34743335 IRF6 0.89 1.08 0.35 - 3.30 0.87 0.90 0.26 - 3.15 
rs642961 IRF6 0.89 0.97 0.63 - 1.50 0.39 0.81 0.50 - 1.32 
rs7590268 THADA 0.86 0.97 0.71 - 1.33 0.25 1.20 0.88 - 1.64 
rs4332945 DYSF 0.88 1.03 0.73 - 1.43 0.82 1.04 0.73 - 1.48 
rs2303596 DYSF 0.46 1.12 0.83 - 1.50 0.69 0.94 0.68 - 1.29 
rs227782 DYSF 0.55 0.93 0.72 - 1.19 0.20 1.18 0.91 - 1.53 
rs115200552 MSX1 0.33 1.31 0.76 - 2.27 0.39 1.27 0.73 - 2.18 
rs12532 MSX1 0.68 0.95 0.74 - 1.21 0.16 0.83 0.64 - 1.08 
rs2674394 Gene Desert 0.08 1.32 0.97 - 1.80 0.46 0.87 0.60 - 1.26 
rs651333 TULP4 0.72 1.05 0.81 - 1.36 0.44 0.90 0.68 - 1.18 
rs6558002 EPHX2 0.78 0.96 0.70 - 1.30 0.14 1.25 0.93 - 1.69 
rs987525 8q24 0.06 0.78 0.60 - 1.02 0.56 0.92 0.70 - 1.21 
rs894673 FOXE1 0.43 0.90 0.70 - 1.17 0.31 0.87 0.66 - 1.14 
rs3758249 FOXE1 0.46 0.91 0.70 - 1.17 0.41 0.89 0.68 - 1.17 
rs7078160 VAX1 0.04a 1.32 1.02- 1.72 0.17 1.22 0.92 - 1.63 
rs4752028 VAX1 0.11 0.82 0.64 - 1.05 0.27 0.87 0.67 - 1.12 
rs10785430 ADAMTS20 0.48 0.91 0.69 - 1.19 0.83 0.97 0.73 - 1.29 
rs9574565 SPRY2 0.19 1.18 0.92 - 1.50 0.70 0.95 0.73 - 1.24 
rs8001641 SPRY2 0.65 1.09 0.75 - 1.59 0.75 0.93 0.62 - 1.41 
rs17563 BMP4 0.49 0.89 0.65 - 1.23 0.61 0.92 0.66 - 1.28 
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rs1258763 GREM1 0.45 1.10 0.86 - 1.40 0.65 1.06 0.82 - 1.37 
rs8049367 ADCY9 0.56 1.08 0.83 - 1.40 0.49 1.10 0.84 - 1.44 
rs16260 CDH1 0.10 0.70 0.46 - 1.07 0.12 1.33 0.93 - 1.91 
rs11642413 CDH1 0.85 0.97 0.73 - 1.30 1.00 1.00 0.74 - 1.35 
rs1546124 CRISPLD2 0.49 0.89 0.65 - 1.23 0.30 1.18 0.86 - 1.61 
rs4783099 CRISPLD2 0.78 1.04 0.81 - 1.33 0.17 1.20 0.92 - 1.56 
rs8069536 NTN1 0.66 0.94 0.72 - 1.23 0.31 1.15 0.88 - 1.50 
rs8081823 NTN1 0.80 0.96 0.73 - 1.27 0.33 0.86 0.64 - 1.16 
rs17760296 NOG1 0.71 1.21 0.44 - 3.32 0.66 1.29 0.42 - 3.99 
rs227731 NOG1 0.61 1.08 0.80 - 1.46 0.53 1.11 0.81 - 1.52 
rs7224837 AXIN2 0.62 1.11 0.73 - 1.69 0.80 1.06 0.67 - 1.68 
rs3923086 AXIN2 0.15 2.86 0.64 - 12.83 0.40 0.00 0.00 - NA 
rs17820943 MAFB 0.93 1.01 0.75 - 1.36 0.72 0.94 0.68 - 1.30 
rs13041247 MAFB 0.80 1.04 0.77 - 1.40 0.99 1.00 0.72 - 1.38 
rs11696257 MAFB 0.87 1.02 0.76 - 1.38 0.76 0.95 0.69 - 1.31 
aLoci that reached nominal significance 
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Table S4: Case-control analyses for Nigeria 





p OR 95% CI p OR 95% CI 
rs1801131 MTHFR 0.42 1.17 0.80 - 1.70 0.28 0.62 0.26 - 1.47 
rs1801133 MTHFR 0.07 1.53 0.96 - 2.45 0.73 0.83 0.29 - 2.37 
rs766325 PAX7 0.56 0.90 0.64 - 1.27 0.07 0.50 0.27 - 1.07 
rs742071 PAX7 0.05 1.30 1.00 - 1.67 0.93 1.02 0.65 - 1.62 
rs560426 ABCA4 0.77 0.96 0.75 - 1.24 0.94 0.98 0.63 - 1.55 
rs481931 ABCA4 0.12 1.40 0.92 - 2.12 0.89 0.94 0.39 - 2.25 
rs4147811 ABCA4 7.48E-03a 1.72 1.15 - 2.56 0.44 1.34 0.64 - 2.80 
rs138751793 ARHGAP29 0.12 1.69 0.86 - 3.32 0.57 1.43 0.41 - 4.93 
rs6677101 SLC25A24 0.66 0.94 0.72 - 1.23 0.08 0.63 0.38 - 1.06 
rs861020 IRF6 0.90 1.02 0.70 - 1.49 0.78 0.91 0.47 - 1.77 
rs34743335 IRF6 0.28 2.16 0.51 - 9.08 0.06 9.33 0.58 - 150.60 
rs642961 IRF6 0.60 0.89 0.57 - 1.38 0.67 0.85 0.39 - 1.82 
rs7590268 THADA 0.89 0.98 0.71 - 1.35 0.66 0.87 0.48 - 1.60 
rs4332945 DYSF 0.51 1.13 0.79 - 1.60 0.55 1.21 0.66 - 2.22 
rs2303596 DYSF 0.14 1.28 0.92 - 1.77 0.21 0.63 0.31 - 1.30 
rs227782 DYSF 0.79 0.97 0.74 - 1.25 0.29 0.77 0.48 - 1.24 
rs115200552 MSX1 0.23 0.59 0.24 - 1.41 0.15 1.93 0.78 - 4.79 
rs12532 MSX1 0.49 0.91 0.71 - 1.18 0.15 0.72 0.45 - 1.13 
rs2674394 Gene Desert 0.81 1.04 0.74 - 1.47 0.97 1.01 0.54 - 1.89 
rs651333 TULP4 0.51 0.91 0.68 - 1.21 0.12 1.45 0.91 - 2.32 
rs6558002 EPHX2 0.92 0.98 0.71 - 1.36 0.80 1.08 0.62 - 1.86 
rs987525 8q24 0.74 0.96 0.73 - 1.25 0.31 0.78 0.49 - 1.26 
rs894673 FOXE1 0.49 1.10 0.84 - 1.46 0.73 1.09 0.67 - 1.79 
rs3758249 FOXE1 0.40 1.13 0.85 - 1.18 0.74 1.09 0.66 - 1.78 
rs7078160 VAX1 0.63 1.07 0.80 - 1.44 1.00 1.00 0.59 - 1.70 
rs4752028 VAX1 0.68 1.06 0.82 - 1.36 0.98 0.99 0.63 - 1.57 
rs10785430 ADAMTS20 0.77 1.04 0.79 - 1.36 0.67 0.90 0.55 - 1.47 
rs9574565 SPRY2 0.57 0.92 0.70 - 1.21 0.77 0.93 0.58 - 1.49 
rs8001641 SPRY2 0.80 0.94 0.58 - 1.52 0.75 1.13 0.52 - 2.45 
rs17563 BMP4 0.29 1.21 0.85 - 1.72 0.38 1.31 0.72 - 2.37 
rs1258763 GREM1 0.46 1.10 0.85 - 1.42 0.84 0.95 0.61 - 1.50 
rs8049367 ADCY9 0.09 1.26 0.97 - 1.64 0.11 0.66 0.39 - 1.11 
rs16260 CDH1 0.78 1.06 0.71 - 1.58 0.53 0.78 0.37 - 1.68 
rs11642413 CDH1 0.62 0.93 0.69 - 1.25 0.33 0.75 0.42 - 1.34 
rs1546124 CRISPLD2 0.62 0.93 0.68 - 1.26 0.51 0.83 0.48 - 1.44 
rs4783099 CRISPLD2 0.98 1.00 0.77 - 1.31 0.04a 0.58 0.34 - 0.98 
rs8069536 NTN1 0.06 1.28 0.99 - 1.66 0.62 1.12 0.71 - 1.78 
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rs8081823 NTN1 0.30 0.85 0.63 - 1.15 0.67 0.89 0.53 - 1.51 
rs17760296 NOG1 0.29 1.45 0.73 - 2.88 0.11 2.21 0.81 - 6.02 
rs227731 NOG1 0.83 0.97 0.70 - 1.34 0.56 1.17 0.68 - 2.02 
rs7224837 AXIN2 0.71 0.92 0.60 - 1.42 0.67 1.16 0.58 - 2.35 
rs3923086 AXIN2 0.35 0.00 0.00 - NA 0.56 0.00 0.00 - NA 
rs17820943 MAFB 0.81 1.04 0.76 - 1.42 0.21 1.38 0.83 - 2.30 
rs13041247 MAFB 0.81 1.04 0.76 - 1.42 0.22 1.38 0.83 - 2.30 
rs11696257 MAFB 0.78 1.05 0.77 - 1.43 0.21 1.38 0.83 - 2.31 





p OR 95% CI p OR 95% CI 
rs1801131 MTH R 0.61 1.14 0.68 - 1.91 0.36 1.27 0.76 - 2.10 
rs1801133 MTHFR 0.17 1.56 0.82 - 2.95 0.15 1.59 0.84 - 3.00 
rs766325 PAX7 0.87 0.96 0.61 - 1.52 0.38 0.80 0.49 - 1.31 
rs742071 PAX7 0.02a 1.48 1.05 - 2.08 0.27 1.22 0.86 - 1.74 
rs560426 ABCA4 0.98 1.01 0.71 - 1.41 0.63 1.09 0.77 - 1.56 
rs481931 ABCA4 0.66 0.86 0.43 - 1.71 2.87E-03a 2.10 1.28 - 3.46 
rs4147811 ABCA4 0.02a 1.88 1.11 - 3.18 0.05 1.72 1.00 - 2.95 
rs138751793 ARHGAP29 0.04a 2.30 1.04 - 5.09 0.80 1.15 0.39 - 3.39 
rs6677101 SLC25A24 0.88 1.03 0.72 - 1.47 0.35 0.83 0.57 - 1.22 
rs861020 IRF6 0.59 0.87 0.52 - 1.46 0.87 1.04 0.63 - 1.74 
rs34743335 IRF6 0.38 2.79 0.25 - 30.91 0.16 3.20 0.58 - 17.63 
rs642961 IRF6 0.20 0.66 0.34 - 1.26 0.97 1.01 0.57 - 1.80 
rs7590268 THADA 0.94 1.02 0.67 - 1.55 0.87 0.96 0.61 - 1.52 
rs4332945 DYSF 0.63 1.13 0.70 - 1.81 0.62 1.13 0.70 - 1.84 
rs2303596 DYSF 0.89 0.97 0.60 - 1.57 0.05 1.51 0.99 - 2.31 
rs227782 DYSF 0.88 1.03 0.73 - 1.45 0.76 0.95 0.66 - 2.56 
rs115200552 MSX1 0.16 0.37 0.09 - 1.56 0.68 0.80 0.28 - 2.30 
rs12532 MSX1 0.25 0.82 0.58 - 1.15 0.82 0.96 0.67 - 1.37 
rs2674394 Gene Desert 0.57 1.14 0.73 - 1.80 0.97 0.99 0.62 - 1.59 
rs651333 TULP4 0.40 0.85 0.58 - 1.25 0.93 0.98 0.67 - 1.45 
rs6558002 EPHX2 0.53 0.87 0.55 - 1.36 0.86 1.04 0.67 - 1.63 
rs987525 8q24 0.44 0.87 0.61 - 1.24 0.81 0.96 0.66 - 1.38 
rs894673 FOXE1 0.15 1.30 0.91 - 1.87 0.78 0.94 0.63 - 1.41 
rs3758249 FOXE1 0.14 1.31 0.91 - 1.87 0.89 0.97 0.65 - 1.44 
rs7078160 VAX1 0.17 1.30 0.89 - 1.89 0.37 0.82 0.53 - 1.27 
rs4752028 VAX1 0.42 1.15 0.82 - 1.62 0.96 1.01 0.71 - 1.44 
rs10785430 ADAMTS20 0.53 0.89 0.61 - 1.29 0.27 1.23 0.85 - 1.77 
rs9574565 SPRY2 0.90 0.98 0.68 - 1.40 0.34 0.83 0.57 - 1.22 
rs8001641 SPRY2 0.71 0.88 0.47 - 1.67 0.85 0.94 0.48 - 1.82 
rs17563 BMP4 0.17 1.38 0.87 - 2.18 0.64 1.12 0.69 - 1.82 
Page 44 of 49
http://mc.manuscriptcentral.com/jdr






























































rs1258763 GREM1 0.64 1.09 0.77 - 1.53 0.31 1.20 0.84 - 1.71 
rs8049367 ADCY9 0.09 1.36 0.96 - 1.93 0.45 1.15 0.80 - 1.66 
rs16260 CDH1 0.75 1.09 0.65 - 1.82 0.85 0.94 0.53 - 1.68 
rs11642413 CDH1 0.31 0.81 0.53 - 1.23 0.50 1.15 0.77 - 1.71 
rs1546124 CRISPLD2 0.49 0.87 0.57 - 1.31 0.82 0.95 0.62 - 1.45 
rs4783099 CRISPLD2 0.73 1.07 0.75 - 1.52 0.83 0.96 0.66 - 1.39 
rs8069536 NTN1 0.19 1.26 0.89 - 1.78 0.12 1.33 0.93 - 1.92 
rs8081823 NTN1 0.85 0.96 0.65 - 1.42 0.10 0.70 0.45 - 1.08 
rs17760296 NOG1 0.19 1.71 0.76 - 3.86 0.80 1.15 0.39 - 3.40 
rs227731 NOG1 0.31 0.79 0.50 - 1.25 0.44 1.18 0.77 - 1.82 
rs7224837 AXIN2 0.97 1.01 0.58 - 1.78 0.61 0.85 0.46 - 1.57 
rs3923086 AXIN2 0.46 0.00 0.00 - NA 0.48 0.00 0.00 - NA 
rs17820943 MAFB 0.91 1.02 0.67 - 1.56 0.62 1.11 0.73 - 1.70 
rs13041247 MAFB 0.94 1.02 0.67 - 1.54 0.61 1.12 0.73 - 1.70 
rs11696257 MAFB 0.91 1.02 0.67 - 1.56 0.59 1.12 0.74 - 1.71 
aLoci that reached nominal significance 
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Table S5: Other rare and/or potentially aetiologic variants observed in seven sequenced genes  
HGVS HGVp α ¶ b Polyphen-2  SIFT § ¥ Reference 
ARHGAP29 
c.560-199T>C N/A 1 NSCLP N/A N/A N/A β N/A dbSNP 
c.1144-18T>C N/A 2 
1 NSCLP and I 
NSCL 
N/A 
N/A N/A β,µ N/A dbSNP 
c.2738C>T p.Ser913Leu 4 
2 NSCLP, 1 
NSCL and 1 CPO 
4 d 
Benign Deleterious N/A N/A dbSNP 
c.2957T>C p.Ile986Thr 1 NSCLP N/A Benign Tolerated N/A N/A dbSNP 
c.2962G>T p.Asp988Tyr 2 
NSCLP 1 d, 1 g Probably 
Damaging Deleterious N/A N/A dbSNP 
c.3023G>A p.Arg1008Lys 2 
1 NSCLP and 1 
CPO 
N/A 
Benign Tolerated N/A N/A dbSNP 
VAX1 
c.390G>A p.Arg130Arg 1 NSCPO N/A Benign Tolerated ε N/A Novel 
c.429+37G>C N/A 1 NSCLP N/A N/A N/A β N/A 1000Genome 
c.429+50C>A N/A 4 
1 NSCLP, 1 
NSCL and 2 CPO 
N/A 
N/A N/A µ λ  1000Genome 
c.693C>A p.Ala231Ala 4 
1 NSCLP and 3 
NSCPO 
N/A 
Benign Tolerated γ, ε λ Novel 
c.754G>T p.Gly252Cys 1 NSCL e 
Probably 
Deleterious N/A N/A Novel 
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c.703G>A p.Ala235Thr 2 
NSCLP 1 c, 1 d Probably 
Damaging Deleterious N/A N/A dbSNP and ExAC 
c.1223C>T p.Pro408Leu 1 
CPO d Probably 
Damaging Deleterious N/A N/A dbSNP and ExAC 
MSX1 
c.95C>T p.Ala32Val 4 
2 NSCL and 2 
C O 
N/A 
Benign Tolerated η,ε N/A ExAc 
c.218C>T p.Pro73Leu 3 
NSCL 2 d, 1 f Possibly 
Damaging Deleterious N/A N/A dbSNP 
c.522G>A p.Lys174Lys 1 
NSCL N/A 
Benign Tolerated N/A N/A Novel 
BMP4 
c.860G>A p.Arg287His 1 NSCL N/A Ben gn Tolerated N/A N/A dbSNP 
c.371-164G>A N/A 2 
1 NSCLP and 1 
NSCL 
N/A 
N/A N/A β, µ N/A Novel 
c.280G>A p.Glu94Lys 1 NSCL N/A Benign Tolerated N/A N/A Novel 
c.228T>A p.Ser76Arg 3 
2 NSCLP and 1 
NSCL 





isoforms N/A N/A dbSNP 
FOXE1 
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α: Total number of cases with variant, ¶: subphenotype of probands in which the variant was observed, b: segregation analyses, c: 
variant was observed in clinically unaffected father, d: variant was observed in clinically unaffected mother, e: variant was absent in 
the only paternal sample available, f: variant was absent in the only maternal sample available, g: no parental sample was available, 
§: Human Splice Finder, ¥: RegulomeDB, β: alteration of Exonic Splicing Silencer (ESS) Site, µ: creation of new Exonic Splicing 
Enhancer (ESE) site, δ: Alteration of the wildtype (WT) donor site, ε: alteration of an ESE site, γ: creation of new Acceptor site with 
branch points, η: creation of new Donor site, λ: 2b - Likely to affect binding of EZH2, N/A: Not Applicable, NSCLP: nonsyndromic 
cleft lip and palate, NSCL: nonsyndromic cleft lip only, CPO: cleft palate only. All analyses were based on genome assembly number 
GRCh37/hg19, 2009 (http://genome.ucsc.edu). 
 
c.107C>T p.Thr36Met 1 
NSCLP d Possibly 
Damaging Deleterious N/A N/A ExAc 
c.569C>G p.Pro190Arg 6 
3 NSCLP, 2 
NSCL and 1 CPO 
1 c, 2 d, 
1 e, 2 f 
Possibly 
Damaging Deleterious N/A N/A dbSNP 
MAFB 
c.-1G>A N/A 2 
1 NSCL and 1 
CPO 
N/A 
N/A N/A δ N/A dbSNP 
c.-75C>A N/A 1 NSCLP N/A N/A N/A N/A λ dbSNP 
c.603G>C p.Ala201Ala 1 NSCL N/A Benign Tolerated N/A N/A Novel 
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Department of Biochemistry and Biotechnology, 
Kwame Nkrumah University of Science and Technology, 
PMB, University Post Office, Kumasi, Ghana. 
6th June 2016 
 
Editor-in-Chief, 




Re: “Association studies and direct DNA sequencing implicate some known genetic 
susceptibility loci in the etiology of nonsyndromic orofacial clefts in sub-Saharan 
African populations”: JDR-16-0113.R2 
We are submitting a revised version of the above manuscript to your journal for publication. This 
revision is in response to the reviews’ comments. As requested by the reviewers, we have now 
added national prevalence data for Nigeria (though none exists for Ghana and Ethiopia) in the 
introduction. In the discussion, we have also hypothesized the possible existence of protective 
genetic variants in the African genome that may reduce OFC susceptibility.  
Responses to reviewers’ comments are shown in the next page. We thank the reviewers for their 
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Response to Reviewers’ comment 
Thank you for making the revisions to your very interesting manuscript. The edits to the tables and 
results are definitely an improvement. I just have one more request. Would you please add in the 
incidence of OFC types in Africans? Right now you have only stated the global incidence but this is 
less relevant for your study. The reader needs a bit more context. I for one, would like to know if it is 
still true to say that the incidence of NSCLP is lower in Africans. This information plus appropriate 
citation should be added to the introduction. In the discussion, it would be important to reference the 
incidence especially if it is much different than for Europeans. How would you reconcile the idea that 
the incidence is lower but the same genetic variants are involved? Does this mean there are 
protective variants somewhere in the genome? It would be worth mentioning this. 
Response: we have added “Though there is no national prevalence data for Ghana and 
Ethiopia, a prevalence estimate of 0.5 per 1000 has been observed for Nigeria (Butali et al. 
2014a)” to the introduction. 
We have dedicated the last paragraph of the discussion to elucidating the implications of the 
lower incidence in Africans, though Africans may share similar or same genetic susceptibility 
variants with Asians and Europeans. 
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